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ABSTRACT 
 
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in Pkd1 
or Pkd2, genes encoding for polycystin-1 (PC-1) and polycystin-2 (PC-2), respectively. ADPKD 
is characterized by the progressive growth of numerous fluid-filled renal cysts. Cyst formation 
and growth depends on proliferation of the cyst-lining epithelial cells and fluid secretion into the 
cyst lumen. ADPKD cystogenesis is highly influenced by non-genomic factors, many of which 
elicit their effects via cAMP-dependent pathways. Understanding mechanisms mediating the 
effects of cystogenic agents is crucial for the future development of ADPKD therapy. 
Previous work has shown that cells derived from the epithelial-lining of renal cysts from 
patients with ADPKD (ADPKD cells) have an increased affinity for the hormone ouabain.  
ADPKD cells respond to ouabain by an increased rate of cell proliferation. This effect depends 
on binding of ouabain to the Na,K-ATPase which induces activation of Src kinase, epidermal 
growth factor receptor (EGFR), and the extracellular regulated kinase (ERK1/2) pathway.  
The objective of the current study was to determine the role of ouabain in mechanisms 
of fluid secretion and cyst growth in ADPKD. Studies were carried out in human ADPKD cells, 
embryonic kidneys from the Pkd1m1Bei mouse model, and M-1 mouse cortical collecting duct 
cells. 
Results of this study show that physiologic concentrations of ouabain enhance cAMP-
dependent fluid secretion and cyst growth of ADPKD cells grown in culture as monolayers or in 
three-dimensional structures resembling cysts. Additionally, ouabain potentiated the cAMP-
dependent growth of cyst-like dilations in metanephric kidneys from the Pkd1m1Bei mouse model.  
These effects were mediated via activation of the Na,K-ATPase signaling apparatus, located at 
the basolateral domain of ADPKD cells. Intracellular mediators of ouabain’s response included 
the EGFR-Src-ERK pathway. Ouabain alone did not increase fluid secretion and cyst growth. 
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Rather, ouabain treatment altered the phenotype of ADPKD cells to allow enhanced responses 
to cAMP agonists. The potentiating effect of ouabain on cAMP-induced fluid secretion was 
associated with the capacity of ouabain to stimulate anion secretion via the apically located 
cystic fibrosis transmembrane conductance regulator (CFTR). Moreover, ouabain increased 
membrane expression of the CFTR.  Finally, ouabain decreased Na,K-ATPase membrane 
expression and ion transport at the basolateral membrane of ADPKD cells. 
The increased ouabain sensitivity of ADPKD cells depends on an abnormally high 
affinity of the Na,K-ATPase for ouabain. Increased ouabain affinity of the Na,K-ATPase was 
associated with abnormal expression of the C-terminus of PC-1 in M-1 cells.  
Altogether, the study of ouabain’s effects in ADPKD have uncovered a novel role for 
ouabain as a physiologic agent that influences renal cyst growth in ADPKD. In addition, it has 
identified a new mechanism in ADPKD cystogenesis, important for the progression of the 
disease.  
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CHAPTER 1 
 
INTRODUCTION 
 
Structure and Function of the Na,K-ATPase 
The Na,K-ATPase is a ubiquitously expressed ion transport protein present in the 
basolateral membrane of most mammalian cells (63). The activity of this transporter is required 
for maintaining the crucial sodium and potassium gradients that typically exist across cell 
plasma membranes (62). Specifically, the Na,K-ATPase uses energy supplied by the hydrolysis 
of ATP to move three Na+ ions out and two K+ ions into the cell. By maintaining the Na+ and K+ 
gradients, the Na,K-ATPase regulates cellular osmolarity and volume (58). The uneven 
exchange of Na+ and K+ catalyzed by the Na,K-ATPase is electrogenic and contributes to 
maintaining cell plasma membrane potential and the excitable properties of muscle and nervous 
tissue (35). Moreover, the steep transmembrane Na+ gradient that the Na,K-ATPase generates 
drives the secondary transport of various solutes, including amino acids, glucose, and ions such 
as H+, Ca2+, and Cl- (62). In the kidney, specifically, Na,K-ATPase activity is crucial for 
regulating salt and fluid reabsorption as well as regulating a variety of Na+-dependent ion 
transporters (27, 62). 
 
Structurally, the Na,K-ATPase is expressed as a heterodimer of two polypeptides, an α 
and β subunit (62, 63). The α subunit is a large transmembrane protein which contains binding 
sites for Na+, K+ and ATP (63) and is primarily responsible for the ion transport and enzymatic 
properties of the Na,K-ATPase. The α subunit contains the binding site for cardiotonic steroid 
hormones, such as ouabain (62). The β subunit is required for proper membrane targeting and 
expression of the alpha subunit at the cell plasma membrane (34). Additionally, the β subunit 
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has been shown to have a role in cell-cell and cell-matrix adhesion (23). Four isoforms of the α 
subunit (α1, α2, α3, and α4) and three isoforms of the β subunit have been described (14, 15). 
These isoforms vary in their distribution in mammalian cells (13). The α1 subunit is present in all 
cell membranes, while the other α isoforms are expressed in a more tissue-specific manner 
(15). The α2 isoform is expressed primarily in skeletal and cardiac muscle, adipose tissue, and 
the brain (68, 80, 108). The α3 isoform is found in tissues of the nervous system (85, 86). The 
α4 isoform of the Na,K-ATPase is expressed specifically in male germ cells (17). The Na,K-
ATPase β isoforms also have tissue specific expression patterns. Similar to the α1 isoform, the 
β1 polypeptide is found is most tissues (13). The β2 subunit is expressed in skeletal muscle, 
pineal gland, and tissues in the nervous system (3, 101). The β3 subunit of the Na,K-ATPase is 
expressed in a variety of tissues including testis, retina, liver, and lung (8). The α and β subunits 
can associate in different arrangements, generating multiple Na,K-ATPase isozymes, which 
have unique kinetic properties (15). Expression in cells in culture and the use of transgenic mice 
demonstrated that Na,K-ATPase heterogeneity is not a redundant event, but rather serves to 
regulate Na+ and K+ transport according to the specific requirements of each cell (13, 15, 71, 
94). A third polypeptide, known as the γ-subunit, is also associated to the α and β subunits in 
some tissues (33). The γ-subunit, while not required for Na,K-ATPase activity, is important in 
modulating the kinetic properties of Na,K-ATPase (97). In the kidney, the Na,K-ATPase is 
expressed as an α1β1γ heterodimer (13, 30) .    
 
A variety of regulatory mechanisms influence Na,K-ATPase expression and activity. 
Na,K-ATPase expression is regulated by the rate of synthesis and degradation of the α and β 
subunit polypeptides (113). Additionally, expression of the Na,K-ATPase at the plasma 
membrane can be modulated by increasing trafficking of α and β polypeptides from intracellular 
stores to the plasma membrane, or through internalization of the protein and its degradation 
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inside the cell (14). In addition, the function of pre-existing Na,K-ATPase molecules at the 
plasma membrane can be regulated directly by various intracellular and extracellular conditions 
(113). Thus, several ions regulate Na,K-ATPase activity, with changes in intracellular Na+ being 
a potent Na,K-ATPase stimulator. In addition, intracellular kinases, including protein kinase A 
(PKA) and protein kinase C (PKC), and extracellular hormones such as vasopressin, dopamine, 
and insulin can influence Na,K-ATPase activity (15, 29, 32).   
 
The Na,K-ATPase is a signal transduction receptor 
In addition to its classical role as an ion transporter, the Na,K-ATPase can function as a 
signal transduction receptor and scaffolding protein that mediates effects of cardiotonic steroids 
in the cell (7, 70, 132, 133). At the plasma membrane, the Na,K-ATPase interacts with several 
proteins to form a function signaling receptor, the Na,K-ATPase signalosome (93). Important 
interactions in the complex include the binding of the Na,K-ATPase to Src, a non-receptor 
tyrosine kinase, and the epidermal growth factor receptor (EGFR). In particular, the Na,K-
ATPase-Src interaction is critical for the transduction of Na,K-ATPase-mediated signaling (66, 
140). The protein-protein interactions that characterize the Na,K-ATPase signalosome occur 
within and depend on the presence of cholesterol-rich plasma membrane microdomains known 
as caveolae (77, 93, 125).  
 
The Na,K-ATPase signalosome mediates the activation of a variety of cell-specific 
intracellular signaling events independent from alterations in intracellular ion concentrations 
(75). Na,K-ATPase-mediated activation of Src leads to transactivation of EGFR and 
downstream activation of the mitogen activated protein kinase (MAPK) pathway and 
phosphorylation of extracellular regulated kinase (ERK1/2) (132, 133). Additionally, stimulation 
of Na,K-ATPase signaling can result in activation of the PLC-γ/PKC pathway resulting in 
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increased IP3-dependent release of intracellular Ca
2+ stores (76). Studies have also shown a 
role for Na,K-ATPase signaling in mediating Ca2+-dependent activation of nuclear factor-kappa 
B (NF-κB) signaling (1).  Na,K-ATPase-dependent signaling can also influence mitochondrial 
production of reactive oxygen species (133). Thus, the Na,K-ATPase regulates important 
physiologic processes via ion transport mechanisms as well as intracellular signaling pathways.  
 
Ouabain is an important physiologic hormone 
Ouabain is a steroid hormone that belongs to a family of compounds known as 
cardiotonic steroids which are present in a variety of different plants and animals (99). Other 
members of this family include digoxin, proscillaridin A, and marionbufagenin (9). All of these 
compounds are specific ligands for the Na,K-ATPase, which contains a highly-conserved 
cardiotonic steroid binding site in an extracellular loop of the α subunit (72). Each α subunit of 
the Na,K-ATPase has a unique and specific cardiotonic steroid affinity which determines the 
differential, tissue-specific effect of cardiotonic steroids (15, 72). For instance, the ubiquitously 
expressed α1 subunit is relatively resistant to the effects of cardiotonic steroids, while the other 
α isoforms have higher affinities for cardiotonic steroids (13). Additionally, there is significant 
inter-species variability in the affinity of the Na,K-ATPase for cardiotonic steroids (14, 15).  
At high, millimolar concentrations, cardiotonic steroids can inhibit Na,K-ATPase catalytic 
activity and ion transport and, thus, regulate Na,K-ATPase-dependent processes in the cells 
(96). For example, cardiotonic steroid-induced inhibition of Na,K-ATPase activity can lead to 
secondary alterations in Na+-dependent transport processes within the cell. In particular, 
cardiotonic steroid inhibition of the Na,K-ATPase can lead to secondary inhibition of the 
Na+/Ca2+ exchanger resulting in increased intracellular Ca2+ accumulation (19).This effect is 
particularly relevant in the heart, where it is responsible for the inotropic and chronotropic effects 
of cardiotonic steroids. 
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Ouabain is a cardiotonic steroid traditionally considered to be exclusively a plant-derived 
product (9). However, careful investigation by Hamlyn and colleagues showed that ouabain is 
indeed an endogenous substance present in human plasma (49-51, 79). Ouabain is released 
from the adrenal gland in response to many different physiologic and pathophysiologic stimuli 
leading to a variety of functional effects (49, 52, 67). Ouabain secretion can be induced by acute 
states of stress or exercise and in response to altered levels of sodium in the circulation (25, 36, 
48). Many studies have linked endogenous ouabain to regulation of arterial blood pressure (6, 
48). Acute saline loading of rodents can cause increases in circulating levels of ouabain, and 
ouabain infusion in rats is sufficient to induce arterial hypertension and cardiac hypertrophy (9). 
In addition to its role in regulation of sodium balance and blood pressure, ouabain has been 
shown to have roles in mood disorders, chemical addictions, and cancer (9). 
At the cellular level ouabain has many diverse, cell-specific effects. Nanomolar 
concentrations of ouabain can increase proliferation and hypertrophic growth of different cell 
types and also alter apoptotic mechanisms in some cells (5, 24, 65, 87, 119). Studies have also 
shown an effect of ouabain on the regulation of salt transport in renal cells and epithelia. 
Specifically, nanomolar concentrations of ouabain can decrease Na+ reabsorption in LLC-PK1 
cells (73, 74, 137). This effect was mediated by ouabain-induced, clathrin-dependent 
internalization of the Na,K-ATPase from the baolateral plasma membrane. Additionally, ouabain 
stimulates the internalization of the apically located Na+/H+ exchanger, NHE3 (21, 92). The 
result of these combined effects appears to be involved in the natriuretic effects of ouabain in 
the renal proximal tubule (137). Studies in human bronchial epithelial cells have reported that 
ouabain modulates the expression of the cystic fibrosis transmembrane conductance regulator 
(CFTR) (144). In this work, nanomolar concentrations of ouabain increased expression and 
delivery of the CFTR to the plasma membrane. Thus, ouabain is a physiologic hormone that 
mediates many important, cell-specific effects. Many of these ouabain-induced effects are 
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mediated by ouabain-Na,K-ATPase binding and activation of Na,K-ATPase-mediated 
intracellular signaling events (93, 99, 100, 132). 
 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
ADPKD is the most common, potentially fatal, inherited disease of the kidney affecting 
1:400-1000 people worldwide (54). In the United States, ADPKD accounts for 4.4% of all cases 
of end-stage renal failure (ESRD) (54). ADPKD is a diverse, systemic pathology with significant 
renal manifestations, as well as defects in the liver, pancreas, arterial vasculature and brain. 
Symptoms of this condition include pain related to enlarged kidneys, cyst and urinary tract 
infection, renal stones, and arterial and cerebral aneurysms. ADPKD is most dramatically 
characterized by the presence of many, progressively enlarging renal cysts. These cysts, which 
originate from renal tubule epithelial cells, grow throughout the kidney and lead to altered renal 
architecture causing end-stage renal disease (ESRD) (37).  
 
ADPKD is caused by mutations in one of two genes, PKD1 or PKD2, which encode for 
polycystin-1 (PC-1) and polycystin-2 (PC-2), respectively (111). Mutations in PC-1 are more 
common, affecting approximately 85% of cases (98). Additionally, mutations in PC-1 typically 
cause a more severe form of the disease compared to mutations in PC-2. Thus, patients 
carrying PC-1 mutations reach  ESRD an average of 17 years earlier than those harboring PC-2 
mutations (55). PC-1 is a large, multi-pass, transmembrane protein with a long, extracellular N-
terminus and a short, intracellular C-terminus (10, 60, 91, 131). PC-1 is expressed in most cells 
in the human body, and, in particular, PC-1 has been shown to localize to primary cilia 
structures in renal tubule cells (142). PC-1 has been associated with many basic properties of 
cell biology. The N-terminus of PC-1 has many functional domains that may be involved in cell-
matrix and cell-cell adhesion and the binding of extracellular ligands. The C-terminus of PC-1 
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has been implicated in a variety of intracellular signaling pathways as well as protein-protein 
interactions. The PC-1 C-tail can be cleaved and translocate to the nucleus to influence 
transcriptional mechanisms. Interestingly, the C-terminus of PC-1 can interact with the 
intracellular C-terminus of PC-2. PC-2 is a multi-pass transmembrane protein with homology to 
known Ca2+ channels (112). Association of PC-1 with PC-2 can form a functional cation-
permeable channel to regulate intracellular Ca2+ concentrations (53). 
 
Cyst growth in ADPKD depends on proliferation of the epithelial cells lining the renal 
cysts as well as secretion of fluid into the growing cyst lumen (40, 111). Cysts begin forming 
when renal epithelial cells carrying germline mutations in the PKD1 or PKD2 gene receive a 
somatic mutation in the healthy allele of PKD1 or PKD2 (37). This causes aberrant proliferation 
of the mutated cells leading to the formation of blister-like structures on the sides of the renal 
tubules. These small cysts enlarge by the combined processes of cell proliferation and fluid 
secretion, and eventually the growing cyst separates from the parent tubule and grows 
autonomously within the renal interstitium. The nature of this somatic mutating event is currently 
not clear. However, it has been demonstrated that acute kidney injury can have a significant 
effect on the induction of cyst growth in ADPKD (110). 
 
Proliferation of cystic epithelial cells depends on a variety of altered intracellular 
conditions. Specifically, abnormal intracellular Ca2+ concentrations and increased cAMP-
dependent signaling are important pathogenic factors in ADPKD (134, 136). Cells derived from 
the cystic epithelium of ADPKD renal cysts (ADPKD cells) exhibit abnormally low Ca2+ levels 
(134). This may be due to the loss of PC-1 or PC-2 function. Aberrant Ca2+ levels allow for 
altered responses to cAMP. For instance, cAMP, which normally has a growth suppressing role 
in renal epithelia, drives enhanced proliferation in ADPKD cells (107, 136). Furthermore, studies 
8 
 
have shown that restoring normal intracellular Ca2+ levels can block the mitogenic effect of 
cAMP in ADPKD cells (134). Mechanistically, low concentrations of intracellular Ca2+ are 
associated with the aberrant activation of B-Raf in response to cAMP agonists (136). This 
activation is a crucial point in mediating the mitogenic effect of cAMP in ADPKD cells.  
 
Fluid secretion in ADPKD is mediated by enhanced secretion of Cl- across cystic 
epithelia (84, 104, 123). ADPKD epithelia regulate transepithelial Cl- movement by a mechanism 
similar to that observed in other secretory epithelia (105). Specifically, Cl- enters from the 
basolateral aspect of the cells via the Na+,K+,2-Cl- co-transporter (NKCC1). The driving force for 
this transporter is provided by the Na+ gradient generated by the basolaterally located Na,K-
ATPase. Cl- is then actively secreted across the apical membrane via the cAMP-dependent 
CFTR . Studies have shown that CFTR is the main mediator of apical anion secretion required 
for increased fluid secretion in ADPKD (20, 28, 104, 138). Increased Cl- secretion across the 
apical membrane of cystic epithelial cells is followed by paracellular movement of Na+ and 
water, which results in enhanced fluid accumulation in the growing cyst lumen (105). 
Interestingly, cAMP-dependent signals regulate the two processes required for progressive cyst 
growth in ADPKD, cell proliferation and fluid secretion (123, 135). Moreover, other agents 
affecting cAMP-dependent signaling and the downstream targets of those signals in ADPKD 
may stimulate the progression of the disease. 
 
Although ADPKD is clearly a genetic condition, progression of the disease is highly 
variable and is influenced by circulating, non-genomic factors, such as vasopressin (AVP), 
prostaglandins, and insulin-like growth factor, which have been shown to influence cyst growth 
in ADPKD via cAMP-dependent pathways (40, 117, 121, 130). For example, it has been shown 
that AVP is a physiologic agent that can increase ADPKD cyst growth via cAMP-dependent 
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mechanisms (121). Importantly, experimental blockade of AVP results in reduced cyst growth in 
experimental models of ADPKD (95, 127). Moreover, recent evidence from a large clinical trial 
(TEMPO3:4) demonstrated the potential therapeutic benefit of targeting inhibition of AVP in 
ADPKD patients (114) . This offers strong support for the pathophysiologic importance of agents 
acting on cAMP-dependent pathways in ADPKD. 
 
Effects of Ouabain in ADPKD 
Previous work has shown that endogenous concentrations of ouabain stimulate 
proliferation of  ADPKD cells (89, 90). ADPKD cells have an abnormally high affinity for ouabain 
despite normal expression of the α1β1 isozyme of the Na,K-ATPase in these cells (90). The 
observed increase in ouabain affinity of cystic epithelial cells may make these cells more prone 
to respond to circulating levels of endogenous ouabain. 
Na,K-ATPase in ADPKD cells is characterized by normal basolateral localization (90). 
Consistent with this finding, ouabain only elicits effects in ADPKD cells when applied to the 
basolateral surfaces. Moreover, physiologic concentrations of ouabain elicit different effects in 
ADPKD cells compared to higher, non-physiologic concentrations. At physiologic 
concentrations, ouabain can activate intracellular signaling events in ADPKD cells. In contrast, 
higher, non-physiologic doses of ouabain become toxic to the cells, consistent with an inhibitory 
role for ouabain at high doses in Na,K-ATPase-mediated ion transport.  
Treatment of ADPKD cells with nanomolar concentrations of ouabain results in a 
significant increase in proliferation of the cells lining the walls of renal cysts (90). This ouabain-
induced proliferation is due to activation of Na,K-ATPase-mediated intracellular signaling events 
(89). Specifically, ouabain treatment of ADPKD cells results in activation of Src and EGFR. 
Ouabain-dependent activation of these kinases stimulates the MAPK pathway in ADPKD cells 
involving the aberrant activation of B-Raf and downstream phosphorylation of ERK1/2. 
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Phosphorylated ERK1/2 translocates to the nucleus in ouabain-treated ADPKD cells and may 
elicit transcriptional changes leading to a proliferative response in the cells. Consistent with this 
finding is a decrease in expression of cyclin-dependent kinase inhibitors p21 and p27 in 
response to ouabain treatment of ADPKD cells. Lower levels of these proteins may contribute to 
the proliferative response of ADPKD cells to ouabain. Taken together, these data demonstrate 
that ouabain is a physiologic agent that may have important cystogenic effects in ADPKD.  
 
Signficance and Specific Aims 
Due to the dependency of ADPKD cystogenesis on different circulating factors and the 
characteristic slow progression of this disease, understanding the non-genetic factors 
influencing disease progression is essential (117, 121). While several compounds are being 
tested for the treatment of ADPKD, there is no approved treatment yet to specifically ameliorate 
the disease. It is vital that basic mechanisms affecting disease progression are better 
understood so strategies may be developed to therapeutically intervene in these pathogenic 
mechanisms and stop progression of the disease. 
 
Ouabain is a physiologic agent that may be important in the progression of ADPKD. 
However, the effect of ouabain on fluid secretion and cyst growth mechanisms in ADPKD 
remains unclear. Due to the important role the Na,K-ATPase has in regulating ion and fluid 
transport in normal renal epithelia, ouabain, acting through the Na,K-ATPase, may have a role 
in regulating ion and fluid transport in cystic epithelia. The objective of the current study was to 
determine the role of endogenous concentrations of ouabain in fluid secretion and cyst growth 
mechanisms in ADPKD. The overall hypothesis guiding this investigation is that, due to the 
increased ouabain affinitiy of ADPKD cells, ouabain will stimulate intracellular signaling events 
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that enhance fluid secretion mechanisms and increase cyst growth in ADPKD. To investigate 
this hypothesis the following specific aims were carried out: 
 
1.) Determine the effect of ouabain on fluid secretion and cyst growth in ADPKD 
cells and kidneys (Chapter 2). 
 
2.) Determine the ion transport mechanisms involved in mediating the effect of 
ouabain on fluid secretion and cyst growth in ADPKD cells and kidneys 
(Chapter 3). 
 
3.) Determine the mechanism of increased ouabain affinity observed in ADPKD 
cells (Chapter 4) 
 
As a disease that is slowly progressing over many years, there could be a great benefit 
for ADPKD patients if the growth trajectory of renal cysts could be lowered, potentially saving 
years of healthy renal function. Such therapies will not be possible without a solid, basic 
understanding of mechanisms mediating the effects of circulating agents affecting disease 
progression. This study addresses critical, mechanistic details regarding the effects of ouabain, 
a physiologic agent that may be influencing progression of ADPKD. Results of this study provide 
significant, novel advances in understanding the role of ouabain in ADPKD. 
 
 
 
 
 
12 
 
CHAPTER 2 
 
MATERIALS AND METHODS 
 
Antibodies Used (chapters 2, 3, and 4)   .................................................................................   13 
Biotinylation and Western Blot Analysis (chapter 3)   ..............................................................   13 
Cell culture (chapters 2, 3, and 4)   .........................................................................................   14 
Chloride Efflux Assay  (chapter 3)   .........................................................................................   14 
Data analysis   .........................................................................................................................   16 
Embryonic organ cultures (chapters 2 and 3)   ........................................................................   16 
Fluid secretion assay (chapters 2 and 3)   ...............................................................................   17 
Immunoblot Analysis (chapters 2, 3, and 4)   ..........................................................................   17 
Immunoflourescence (chapter 3)   ...........................................................................................   18 
Intracellular Sodium Measurement (chapter 3)   .....................................................................   19 
Mice (chapters 2 and 3)   .........................................................................................................   19 
Microcyst cultures (chapters 2 and 3)   ....................................................................................   20 
Na,K-ATPase Activity Assays (chapter 4)   .............................................................................   20 
Real-time RT-PCR analysis (chapter 2)   ................................................................................   21 
RT-PCR Analysis (chapter 4)   ................................................................................................   21 
Rubidium (86Rb) Uptake (chapter 3)   ......................................................................................   22 
Short Circuit Current (chapters 2 and 4)   ................................................................................   22 
Solutions (chapters 2, 3, and 4)   .............................................................................................   23 
 
 
 
13 
 
Antibodies used (chapters 2, 3, and 4) 
Target Antigen Antibody Name (M/P) Source 
α1-Na,K-ATPase a6F (M) DSHB, U. Iowa, Iowa City, IA 
α1-Na,K-ATPase C46B/CB (M) M. Caplan, Yale University, New Haven, CT 
α2-Na,K-ATPase MCB2 (P) K. Sweadner, Mass. Gen. Hospital, Boston, MA 
α3-Na,K-ATPase MA3-915 (M) Affinity Bioreagents, Golden, CO 
α4-Na,K-ATPase 108 (M) Covance Immunology Services, Denver, CO 
β1-Na,K-ATPase M17-P5-F11 (M) Affinity Bioreagents, Golden, CO 
CFTR, C-terminus clone 24-1 (M) R&D Systems, Minneapolis, MN 
α-tubulin clone DM1A (M) Sigma-Aldrich, St. Louis, MO 
NKCC1 T4 (M) DSHB, U. Iowa, Iowa City, IA 
phospho-ERK1/2 sc-7383 Santa Cruz Biotechnology, Santa Cruz, CA 
ERK1/2 sc-94 Santa Cruz Biotechnology, Santa Cruz, CA 
M = monoclonal, P= polyclonal 
DSHB = Developmental Studies Hybridoma Bank 
 
Biotinylation and Western Blot Analysis (chapter 3) 
ADPKD cells (2x105) were grown to confluence in 5%FBS on Transwell filters (24-mm, 0.4 µm 
pore size; Corning Incorporated, Corning, NY) in a 6-well culture plate. Once confluent, 
monolayers were serum starved overnight and then treated without and with ouabain (3 nM) for 
24h or 48h. Monolayers were then washed 3x with ice-cold PBS and then incubated with 0.75 
mg/ml Biotin in 1 ml of PBS, pH 8.0 for 50 min at 4°C, refreshing the biotin solution after 30 min. 
After washing twice with ice-cold PBS and once 100 mM Glycine, cells were  lysed in 500 μL 
RIPA (see Solutions). The soluble supernatants were isolated after centrifugation at 10,000 x g 
for 10 min. Protein concentration was determined by the Bio-Rad Protein Assay (Bio-Rad, 
Hercules, CA). Then lysates with equal amounts of protein were added to streptavidin coated 
magnetic beads and rotated overnight at 4°C. Samples were washed twice in PBS and 
resuspended in 6x BME-loading buffer. Samples were then subjected to SDS-PAGE and 
transferred to nitrocellulose. Membranes were probed and analyzed as descibed below in 
Immunoblot Analysis. 
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Cell culture (chapters 2, 3, and 4) 
Primary cell cultures from NHK epithelial cells and cyst-lining renal epithelial cells from 
patients with ADPKD were prepared from nephrectomy specimens by the PKD Biomaterial Core 
at University of Kansas Medical Center. A protocol for the use of discarded human kidney 
tissues was approved by the Institutional Review Board at the University of Kansas Medical 
Center (KUMC). Cells were seeded and grown in DME/F12 supplemented with 5% heat-
inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 0.1mg/mL streptomycin, 5 µg/mL 
insulin, 5 µg/mL transferrin, and 5 ng/mL sodium selenite (ITS) as described (123).  
Studies described in chapter 4 made use of two clonal cell lines, clone 17 (M-1 C17) and clone 
20 (M-1 C20), developed by our collaborators (107). These cell lines were prepared from mouse 
cortical collecting duct cells (M-1), after stable transfection with a dexamethasone-inducible 
construct containing the membrane targeted C-tail fragment of PC-1. The M-1 C20 cells express 
the PC-1 C-tail upon induction with dexamethasone, while M-1 C17 cells do not express the 
construct and, therefore, serve as a negative control (107). Cells were cultured in DME/F12 
supplemented with penicillin/streptomycin (P/S) and 5% heat-inactivated fetal bovine serum 
(FBS) as described (107). For induction of PC-1 C-tail expression, cells were treated with 1 μM 
dexamethasone and cultures were used 48 h later. Ouabain treatment was performed using 
different concentrations of ouabain on the induced cells, after 24 h starvation in medium 
containing 0.002% FBS and dexamethasone.  
 
Chloride Efflux Assay (chapter 3) 
Cl- efflux was assessed as previously described using a Cl--sensitive flourescent 
indicator, N-[ethoxycarbonylmethyl]-6-methoxyquinolinium bromide  (MQAE) (Life Technologies, 
Grand Island, NY) (128). Briefly, cells were treated as indicated and then loaded with MQAE in 
a Cl--containing Loading Buffer (5.4mM KCl, 122.6mM NaCl, 1.0mM CaCl2, 1.0mM Na2SO4, 0.6 
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NaH2PO4, 2.4 Na2HPO4, 1.0mM MgSO4, 10mM HEPES, 10mM D-Glucose, pH 7.4). Then, Cl
- 
efflux was induced by switching cells to Efflux Buffer (5.4mM KNO3, 122.6mM NaNO3, 1.0mM 
Ca(NO3)2, 1.0mM Na2SO4, 0.6 NaH2PO4, 2.4 Na2HPO4, 1.0mM MgSO4, 10mM HEPES, 10mM 
D-Glucose, pH 7.4) in which Cl- was exchanged for nitrate. In our study, ADPKD cells were 
plated with 1%FBS in a 96-well plate (1 x 104 cells/well). After 24h, cells were serum starved 
overnight in media containing 0.002%FBS. Cells were then treated with and without ouabain for 
48h. 16h prior to the end of the treatment period, cells were loaded with MQAE (7 mM) in 
Loading Buffer maintaining the presence of ouabain in the appropriate wells. At the end of the 
treatment and dye-loading steps, cells were washed three times in Loading Buffer with and 
without CFTR(inh)-172 (30 µM). During the third wash, forskolin (5 µM) was added for 10 
minutes to the buffer on wells with and without ouabain. Control cells received no experimental 
treatments in the wash buffer. For each treatment condition parallel samples were treated on 
the same microplate in the absence and presence of CFTR(inh)-172. Media was then quickly 
switched to Efflux Buffer maintaining the presence of experimental treatments. Flourescence 
measurments were taken using the excitation/emission pair 360nm/460nm every minute for 10 
min using a microplate reader (HTS Synergy). Cl- efflux was calculated as the difference 
between the measured fluorescence in each well at a given time point (Ft) and the initial 
fluorescence of the sample just before switching to Efflux Buffer (F0), expressed in arbitrary 
flourescence units. CFTR-dependent efflux was determined as the difference in fluorescence 
change (Ft-F0)  between samples treated with and without CFTR(inh)-172 for a given 
experimental treatment.  
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Data analysis.   
Statistical significance of the differences between means was determined by one-way 
ANOVA with a Student Newman-Keuls post-test for multiple comparisons or unpaired t-test for 
single comparisons. Statistical significance was defined as P < 0.05. 
 
Embryonic organ cultures (chapters 2 and 3) 
Metanephric kidneys were dissected under sterile conditions and were transferred to 
Transwell filters (24-mm, 0.4 µm pore size; Corning Incorporated, Corning, NY) in a 6-well 
culture plate.  Metanephroi were cultured at an air-fluid interface with serum-free medium 
containing equal volumes of DME/F12 supplemented with 2mM L-glutamine, 10 mM HEPES, 
ITS, 25 ng/mL prostaglandin E1, 32 pg/mL triiodothyronine, and penicillin/streptomycin.  The 
medium was supplemented with 100 µM 8-Br-cAMP in the absence or presence of 30 nM 
ouabain, which was applied to the lower chamber of the culture inserts. The higher amounts of 
ouabain used for the organ culture, compared to ADPKD cultures, correspond to the known 
differences in ouabain affinity of the Na,K-ATPase of rodents and humans (16). Some 
experiments were also performed in the absence or presence of 2 μM of Tyrphostin AG1478, 10 
μM of PP2 or 1 μM of U0126 (chapter 2). Metanephroi were maintained at 37°C in a humidified 
chamber containing 5% CO2 and 95% air and were observed, under light microscopy, daily for 
four days after treatment. Images were captured at culture days 0, 1, 2, 3 and 4. Quantification 
of total kidney and dilated tubule area was performed on the images using analySIS software as 
previously described (81).  Fractional cyst area was calculated as the ratio of the total dilated 
cystic tubule area divided by the area of the whole kidney. 
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Fluid secretion assay (chapters 2 and 3) 
Confluent NHK and ADPKD monolayers were established on 12-mm permeable 
Snapwell™ inserts (Corning Incorporated, Corning, NY) in 6-well tissue culture plates as 
previously described (90). Cells were cultured for 1 week, until a tight epithelium was 
established, as determined by the achievement of a transepithelial electrical resistance across 
the cell monolayer (90). Then, cells were serum starved in our basal DME/F12 media for 24 h 
as described (90) and the basolateral side of the cell monolayers were treated with 3 nM 
ouabain, in the absence and presence of 5 µM forskolin or 100 µM 8-Br-cAMP.  Control 
monolayers were incubated in basal media. Fresh medium (150 µl) was placed on the apical 
surface of the cells, and mineral oil was layered over the top of the medium to prevent 
evaporation. Cultures were incubated at 37 oC for an additional 24 h and the apical medium was 
collected and measured as described (124). Fluid secretion data were expressed as ul/hour/cm2 
where positive values indicate fluid secretion and negative values indicate fluid absorption. For 
some experiments, monolayers were treated in the absence or presence of 2 µM of the EGFR 
inhibitor Tyrphostin AG1478, 10 µM of the Src inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyrimidine) or 1 µM  of the MEK inhibitor U0126 (chapter 2). Additionally, 
To analyze the involvement of CFTR in any observed fluid secretion, CFTR(inh)-172 (10 µM), 
was added to the apical media applied to monolayers in a certain set of experiments (chapter 3) 
 
Immunoblot Analysis (chapters 2, 3, and 4) 
After the different treatment conditions, were washed twice in ice-cold PBS and lysed in 
RIPA buffer (see Solutions). Total protein content in the cleared lysates was determined using 
the dye-binding assay from Bio-Rad (Hercules, CA, USA). Equal amounts of protein were 
resolved by SDS-PAGE and blotted onto nitrocellulose membranes. Membranes were then 
probed for expression of the proteins of interest using specific primary antibodies (see 
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Antibodies). For experiments analyzing protein phoshorylation (chapter 4 – phospho-ERK1/2 
analysis), membranes were first probed with phospho-secific primary antibodies. The 
membranes were then stripped and reprobed using a primary antibody specific for the total form 
of the protein of interest. Horseradish-peroxidase conjugated, species-specific secondary 
antibodies and chemiluminescence were used for detection. Protein loading levels were 
controlled for by immunoblotting for α-tubulin expression levels. Protein expression was 
determined by densitometry. Data were normalized against α-tubulin as a loading control and 
reported as values relative to expression levels in untreated control cells for each individual 
experiment. 
 
Immunoflourescence (chapter 3) 
ADPKD cells were grown to confluency on Snapwell™ inserts (12-mm, 0.4 μm pore size; 
Corning Incorporated, Corning, NY) in 6-well tissue culture plate. Following overnight serum 
starvation, cells were treated with and without ouabain (3 nM) for 24h. Cells were then fixed in 
100% methanol for 45 min at -20 oC and were analyzed by immunocytochemistry as previously 
described. Expression of the Na,K-ATPase was detected using a monoclonal primary antibody 
that recognizes the α1 subunit of the Na,K-ATPase, a6F (see Antibodies)  followed by exposure 
to an Alexa Flour 594 secondary antibody (Life Technologies, Grand Island, NY). Cells were 
mounted with Slow Fade ® Gold anti-fade reagent with DAPI (Life Technologies, Grand Island, 
NY). Samples were analyzed using a Zeiss LSM510 confocal microscope. Images were 
acquired in Multitrack channel mode with LSM510 (v3.2) softwre and a Plan-Apochromat 
63x/1.4 Oil DIC objective with a frame size of 1024x1024 pixels and a zoom factor of 2. z-line 
views were obtained by averaging 10 sections over a line at each z position in 1.0 µm steps. 
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Intracellular Sodium Measurement (chapter 3) 
Changes in intracellular Na+ were determined using  the fluorescent dye Sodium Green 
tetra acetate (Life Technologies, Grand Island, NY) as described (56). ADPKD cells (2x104) 
were grown in the wells of an 8-chamber slide.  Following overnight serum starvation, cells were 
treated with and without ouabain (3 nM) in media containing the flourescent compound for 30, 
60, and 90 min. Then images of individual cells or groups of cells were analyzed using the 
excitation/emission pair 470/490 nm on an inverted microscope attached to a digital CCD 
camera. Mean flourescence intensity was measured in arbitratry flourescence units and 
expressed relative to mean flourescence intensity of untreated control cells. During analysis, 
samples were maintained at at 37 °C by use of a heating chamber regulated on-line with the 
system acquisition control. 
 
Mice (chapters 2 and 3) 
All experimental protocols involving mice, were approved by the KUMC Institutional 
Animal Care and Use Committee. Pkd1m1Bei mice were originally obtained from the Mutant 
Mouse Regional Resource Center (University of North Carolina, Chapel Hill, NC) (57) and were 
stabilized onto a C57BL/6 background (81).  Mice heterozygous for Pkd1 were mated and 
embryos from timed-pregnant females were removed at embryonic day 15.5 (E15.5).  Embryo 
genotyping showed the Pkd1 allele was  inherited with approximate expected Mendelian ratios.  
Cftrm1UNC (S489X) were also used in this study (chapter 3). These mice are considered to 
exhibit a null CFTR phenotype due to unstable CFTR expression at the mRNA or protein level 
(109). As previously described (81), double heterzygous mice (Pkd1+/-; CFTR+/-) were 
generated and bred to yield litters of mice deficient in both PC-1 and CFTR. Embryonic kidneys 
from these litters were used at day E15.5  for metanephric organ culture experiments.  
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Microcyst cultures (chapters 2 and 3) 
 NHK and ADPKD cells were suspended at a density of 4000 cells per well in a 96-well 
plate in ice cold type I collagen (PureCol®, Advanced Biomatrix, San Diego, CA) in medium 
comprised of 1:1 DME/F12, 100 U/ml penicillin, 0.1mg/mL streptomycin, ITS, 5 x 10-8 M 
hydrocortisone and 5 x 10-12 M triiodothyronine (defined medium).  After the cell/collagen 
suspension was seeded, the gel was polymerized by warming the culture plates to 37°C.  Cysts 
were induced to grow by pre-treatment for 2 to 4 days with 5 µM forskolin and 5 ng/mL EGF.  
Once the cysts began forming, the agonists were removed and cultures were treated with 
defined medium, in the absence and presence of 3 nM ouabain or 5 µM forskolin, alone or 
together. Some experiments were performed in the absence or presence of 2 μM Tyrphostin 
AG1478, 10 μM PP2 or 1 μM  U0126 (chapter 2). Additionally, some experiments were 
performed in the absence or presence of a specific inhibitor of CFTR, CFTR(inh)-172 (10 µM)  
(chapter 3). Cysts were allowed to grow for 5 to 7 days in culture, and then they were fixed with 
0.5% buffered formalin in PBS. Cultures were photographed and the diameters of individual 
cysts (>100 μm in diameter) were measured and used to calculate a total surface area using 
analySIS software (Lakewood, CO) as described previously (95). Data were expressed as 
average total surface area + SEM for each culture condition.  
 
Na,K-ATPase Activity Assays (chapter 4) 
Na,K-ATPase activity was determined by measuring the initial rate of release of  32Pi 
from  γ[32P]-ATP in homogenates from M-1 C17 and M-1 C20 cells as previously described (90). 
Briefly, samples were incubated at 37˚C for 30 min in a final volume of 0.25 mL of medium 
containing 120 mM NaCl, 30 mM KCl, 3 mM MgCl2, 0.2 mM EGTA, 2 mM sodium azide, 30 mM 
Tris-HCl (pH 7.4) in the absence and presence of the indicated concentrations of ouabain, and 3 
mM ATP with 0.2 µCi γ[32P]ATP. Specific hydrolysis of ATP dependent on the Na,K-ATPase 
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was determined as that sensitive to 1 mM ouabain. Curve fitting of the data for ouabain 
inhibition of Na,K-ATPase activity was performed using Marquardt least-squares nonlinear 
regression as previously described (90).    
 
Real-time RT-PCR analysis (chapter 2): 
ADPKD cells and NHK cells were treated with 8-Br-cAMP (100 µM) or ouabain (3 nM) 
alone or in combination, and total RNA was extracted using with the RNA easy mini kit (Qiagen 
Sciences, Maryland, USA). cDNA was synthesized using 1 μg of RNA with Omniscript RT Kit 
(Invitrogen) and oligo-dT primers. (Invitrogen). Real-time qPCR was performed using ABI Prism 
7900 (Applied Biosystems, Foster City, CA, USA) and SYBR green PCR master mix 
(Warrington, UK) following the manufacturer’s protocol. In brief, the reaction mixture (total 
volume, 25 μl) contained 8μl of 1:10 diluted cDNA, 5′-GTAACCCGTTGAACCCCATT-3′ 
(antisense) 5′-CCATCCAATCGGTAGTAGCG-3′(sense) to amplify human 18 S rRNA. NKCC1 
and CFTR was amplified using the following primers: 5′-ACAATGGCGAATGGTGACT-3′ 
(antisense) and 5′-CATGGGGTTACTTTTTGGTTAC-3′ (sense) for NKCC1, 5′- 
GGAAAAGGCCAGCGTTGTC-3′ (antisense) 5′-CAGGCGCTGTCTGTATCCT-3′ (sense) for 
CFTR at a final concentration of 100 nM and with 12.5 μl of 2 × SYBR green PCR master mix 
kit. Target genes and 18sRNA gene were amplified in the same reaction. All experiments were 
normalized to 18s RNA. Comparative quantification is determined using the 2−ΔΔCt method (78). 
 
RT-PCR Analysis (chapter 4)  
Total RNA from M-1 C17 and M-1 C20 cells was prepared using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany). Complementary DNA was generated by reverse transcription of 
total RNA using SuperScript II reverse transcriptase (Invitrogen, Grand Island, NY, USA) and 
oligo-dT primers (Invitrogen). Primers specific to the various α isoforms of mouse Na,K-ATPase 
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were used to amplify segments of the corresponding cDNAs. These primers contained the 
following  sense (S) and antisense (AS) sequences,: For α1, 5’-
GGGGTTGGACGAGACAAGTAT-3’(S), and 5’-CGGCTCAAATCTGTTCCGTAT (AS); for α2, 5’-
CCACCACTGCGGAAAATGG-3’(S) and 5’-GCCCTTAGACAGATCCACTTGG-3’(AS); for α3 5’- 
GAAGAGGTCTGCCGGAAATAC-3’(S) and 5’- GGTGGTGTGAGGGCGTTAG(AS); and finally, 
for α4, 5’- CAGTGGCGCATTTGTGGTTT-3’(S) and 5’-CAGCGATTCGAGCCAGGTAAA-3’(AS).  
Amplification products were resolved on a 1% agarose gel containing ethidium bromide.  
 
Rubidium (86Rb) Uptake (chapter 3) 
Na,K-ATPase-mediated ion transport was determined by 86Rb uptake as previously 
described (120).  ADPKD cells (2x105) were seeded in 5%FBS on Transwell filters (24-mm, 0.4 
µm pore size; Corning Incorporated, Corning, NY) in a 6-well culture plate and grown to 
confluence. Following overnight starvation, monolayers were treated with and without ouabain 
(3 nM) for 30 min. Monolayers were then placed into 6-well plates containing rubidium flux 
medium (see Solutions)containing 5 uCi 86Rb. Uptake was allowed for 5 min and was then 
terminated by immersing the monolayers in ice-cold, isotonic buffer containing 100 mM MgSO4 
and 137 mM sucrose. Cells were lysed in RIPA buffer (see Solutions) and radioactivity of the 
obtained lysates was measured by scintillation counting. 86Rb uptake was calculated as nmol 
86Rb/mg protein in the cell lysate.   
 
Short Circuit Current (chapters 2 and 4) 
Confluent monolayers of ADPKD cells or M-1 C17 and M-1 C20  were grown on 12-mm 
permeable Snapwell™ inserts (Corning Incorporated, Corning, NY) as previously described 
(90). Monolayers were mounted in Ussing chambers for measurement of short circuit current 
(Isc) using a dual voltage clamp device (Warner Instruments, Hamden, CT) as previously 
23 
 
described (122). Prior to measurement of short circuit current, monolayers were incubated 
either in control media or media containing 3 nM ouabain for 24 hours. Additionally, for analysis 
of the involment of Src in ouabain effects on Isc in M-1 cells, monolayers were pre-treated with 
PP2 (10 µM) for 30 min prior to the addition of ouabain (30 nM) maintaining the presence of 
PP2. Once monolayers were loaded in Ussing chambers and currents stabilized, benzamil (10 
µM) was added to the apical media to block sodium reabsorption and ensure any increase in 
short circuit current was due to apical anion secretion. Forskolin (5 µM) was added basolaterally 
to monolayers to stimulate Isc, and change in Isc (ΔIsc) in response to forskolin was calculated as 
a difference from baseline current, as previously described (4). CFTRinh-172 (10 µM) was 
added apically to determine the involvement of CFTR in any observed increased in Isc. Data are 
expressed as a percentage of the maximum response to forskolin in the untreated monolayers 
 
Solutions (chapters 2, 3, and 4) 
RIPA (cell lysis buffer): 1%NP-40, 0.25% sodium deoxycholate, 1 mM Na3VO4, 1 mM NaF, 1 
mM EDTA (pH 8.0), 150 mM NaCl, 50 mM Tris (pH 7.4), 50 µM phenylarsine oxide, 1x protease 
inhibitor (Roche), 1x phosphatase inhibitor (Roche) . 
Loading Buffer: 5.4mM KCl, 122.6mM NaCl, 1.0mM CaCl2, 1.0mM Na2SO4, 0.6 NaH2PO4, 2.4 
Na2HPO4, 1.0mM MgSO4, 10mM HEPES, 10mM D-Glucose, pH 7.4 
Efflux Buffer: 5.4mM KNO3, 122.6mM NaNO3, 1.0mM Ca(NO3)2, 1.0mM Na2SO4, 0.6 
NaH2PO4, 2.4 Na2HPO4, 1.0mM MgSO4, 10mM HEPES, 10mM D-Glucose, pH 7.4) 
Rubidium flux medium: (Hank’s Balanced Salt Solution + 10 mM HEPES) 
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CHAPTER 3 
 
OUABAIN POTENTIATES cAMP-MEDIATED 
FLUID SECRETION AND CYST GROWTH IN ADPKD 
 
INTRODUCTION 
 
Previous studies have shown that ouabain, in concentrations similar to those circulating in 
blood, stimulates the proliferation of human ADPKD cyst-linning epithelial cells, but has no 
significant effect in normal human kidney (NHK) cells (90). Ouabain binding to the Na,K-ATPase 
activates the EGF receptor (EGFR), the tyrosine kinase Src, and the mitogen activated kinase-
extracellular regulated kinase (MEK-ERK) pathway (90). Many cystogenic factors in ADPKD 
share a common mechanism of action, which involves the MEK-ERK pathway. Increased 
proliferation of renal tubular cells is an essential step in the development of renal cysts (22, 91, 
106). However, cyst expansion also requires the concomitant and continuous addition of fluid 
into the cavity of the growing vesicles, which maintains the shape and turgidity of the cysts. This 
process depends on changes in the salt and fluid transport properties of the ADPKD cells, which 
favor fluid secretion over reabsorption in the cystic epithelium (104, 105). Here, studies were 
conducted to determine whether physiological concentrations of ouabain can affect ADPKD fluid 
secretion and cyst growth. Results from these studies indicate that ouabain can act as a co-
factor enhancing the effects of forskolin and cAMP on fluid secretion and microcyst 
development of human ADPKD cells in culture and on cyst-like dilations in metanephric organ 
cultures of Pkd1m1Bei mice. These effects of ouabain are mediated via the EGFR-Src-MEK 
pathway.  
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RESULTS 
 
Ouabain enhances cAMP-dependent  fluid secretion by the ADPKD epithelium 
Fluid secretion is an essential event in the formation and development of ADPKD cysts (39, 
40). As a first approach to determine the effect of ouabain in cystogenesis, we determined the 
transepithelial movement of fluid from the basal to the apical side of NHK and ADPKD cell 
monolayers. For this, cells were treated for 24 hours without or with 3 nM ouabain, a 
concentration found to be optimal for stimulating ADPKD cell growth (90). Monolayers were also 
treated with either 5 µM forskolin or 100 µM 8-Br-cAMP, alone or in combination with ouabain. 
After 24 h, the amount of fluid present in the upper chamber of the cell monolayer was 
measured as described (124). Untreated NHK monolayers absorbed fluid from the apical to the 
basolateral side (Figure 1A). This is indicated by negative values of fluid secretion. Ouabain had 
no significant effect on fluid transport in NHK monolayers, either when it was used alone, or in 
combination with forskolin or 8-Br-cAMP (Figure 1A). Addition of either forskolin or 8-Br-cAMP 
induced a positive fluid secretion across NHK monolayers, but this fluid transport was not 
significantly different from untreated controls (Figure 1A). These results agree with the small 
stimulatory effects that cAMP agonists have on apical fluid movement in normal dog and human 
kidney cells (83, 84). Similar to NHK monolayers, ADPKD monolayers absorbed fluid in the 
untreated condition, and ouabain alone did not significantly affect epithelial fluid transport by 
ADPKD monolayers (Figure 1B). Both forskolin and 8-Br-cAMP increased fluid secretion in 
ADPKD monolayers (Figure 1B), consistent with previous observations (84). Also, in agreement 
with previous observations (23), forskolin induced a higher level of fluid secretion compared to 
secretion induced by 8-Br-cAMP. (Figure 1B).  Interestingly, the forskolin- and cAMP-dependent 
transepithelial fluid secretion of ADPKD cells was enhanced by the presence of ouabain (Figure 
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1B). These results demonstrate that in ADPKD cells, but not in normal renal cells, ouabain 
enhances the apical delivery of fluid that is induced by forskolin and 8-Br-cAMP.  
 
Ouabain contributes to ADPKD microcyst development 
 When cultured in a three-dimensional matrix of polymerized collagen, ADPKD cells form 
microscopic structures resembling cysts in the presence of EGF and forskolin (105, 123). These 
microcysts are lined by a polarized epithelium that secretes fluid like the wall of native ADPKD 
cysts (139). We have used this in vitro model system to study the effects of ouabain on ADPKD 
cyst formation. For this, NHK and ADPKD cells cultured within collagen matrices were first 
stimulated to form microcysts with EGF and forskolin.  Once the cysts began to form, the 
agonists were removed and the cultures were treated without or with 3 nM ouabain and 5 µM 
forskolin alone or combined. Microcysts were allowed to grow for 5 to 7 days. Then, changes in 
cyst size were quantified and expressed as average total surface area of the microcyst cultures. 
NHK cells showed little microcyst development in response to forskolin and ouabain had no 
effect on NHK microcysts, either when used alone or with forskolin (Figure 2A).  ADPKD 
microcysts exhibited a more robust response to forskolin than NHK cells, presenting greater 
total cyst surface area (Figures 2B).  This confirmed previous observations on the positive role 
of forskolin in promoting ADPKD microcyst growth (105, 123).  In contrast to NHK cells, ouabain 
greatly enhanced cAMP-dependent growth of ADPKD microcysts, but had no effect when used 
alone (Figures 2B).  Altogether, these results show that ouabain acts as a cofactor in a 
synergistic manner with forskolin to increase fluid secretion and accelerate ADPKD cyst growth. 
 
Ouabain exacerbates cAMP-induced cystic progression in metanephric organ cultures 
Metanephric organ cultures of Pkd1m1Bei mice represent a useful tool for studying the 
mechanisms responsible for cystogenesis in an orthologous model of ADPKD. This mouse 
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model carries a mutation in the Pkd1 gene that results in a non-functional PC1 product. Renal 
tubules in embryonic Pkd1m1Bei mice secrete fluid and become dilated in response to 8-Br-cAMP 
(81).  In the current study, we have used Pkd1m1Bei mice to explore the effects of ouabain on 
cyst growth in metanephric organs of this ADPKD mouse model. Embryonic kidneys from wild 
type (Pkd1+/+), heterozygous (Pkd1+/-) or homozygous null (Pkd1-/-) mice were dissected at 
E15.5 and cultured as previously described (81).  Then, the metanephroi were treated with 30 
nM ouabain in the absence or presence of 100 µM 8-Br-cAMP and the development of cystic 
dilations was followed for 4 days, when fractional cyst area was measured. Similar to our results 
in ADPKD monolayers and microcysts, ouabain by itself did not have a significant effect on 
metanephric tubule dilation and cyst formation in the Pkd1+/+, as well as in the Pkd1+/- and Pkd1-
/- embryonic kidneys (Figure 3). In agreement with previous work (81), addition of 8-Br-cAMP 
produced cystic dilations in the metanephroi. These cysts continued expanding during the 
course of the 4 day treatment of the cultures, becoming more marked in the mutated Pkd1 than 
in the wild type mice (Figures 3).  While ouabain alone had no effect, the concomitant addition 
of ouabain and 8-Br-cAMP significantly exacerbated fractional cyst area in the metanephroi. 
This response was greatest in the Pkd1-/- and Pkd1+/- kidneys, reaching a three-fold increase in 
fractional cyst area in the metanephroi from the more severe phenotype (Figure 3B, 3D and 3F). 
Altogether, these results indicate that, in the presence of 8-Br-cAMP, ouabain stimulated 
metanephric cyst development, with the most dramatic effects taking place in Pkd1-/- embryonic 
kidneys. This shows that the effects of ouabain on cyst development are not limited to ADPKD 
cells in culture but also occur in a system that maintains the architecture of the intact renal 
tissue. 
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Ouabain stimulates ADPKD fluid secretion and cyst growth through the EGFR, Src and MEK 
pathway. 
Ouabain exerts its stimulatory effect on ADPKD cell proliferation, via the Na,K-ATPase 
signalosome and its downstream mediators, EGFR, Src and the mitogen activated protein 
kinase (MAPK) pathway (93, 133).  To explore whether the stimulatory effects of ouabain on 
ADPKD cystogenesis involve the Na,K-ATPase signaling machinery, we tested the effects of 
inhibitors of EGFR (Tyrphostin AG1478), Src (PP2) and MEK (U0126) on ouabain and forskolin 
induced fluid secretion in ADPKD cell monolayers, ADPKD microcyst cultures, and Pkd1m1Bei 
metanephric organ cultures. The doses of Tyrphostin AG1478, PP2 and U0126 chosen were 
based on those used previously (89). In fluid secretion experiments, ADPKD cell monolayers 
were grown and treated with the inhibitors mentioned above in the presence of forskolin alone 
or forskolin with ouabain. Inhibition of EGFR, Src and MEK, individually, blocked ouabain-
dependent increases in forskolin-induced fluid secretion by ADPKD monolayers (Figure 4A). In 
three dimensional collagen microcyst experiments, cultures were treated with forskolin alone or 
forskolin with ouabain in the absence or presence of Tyrphostin AG1478, PP2 or U0126. Here, 
the inhibitors also prevented ouabain’s enhancement of forskolin-induced ADPKD microcyst 
growth (Figure 4B). The effect of these inhibitors on microcyst growth was more robust than for 
fluid secretion in ADPKD monolayers. This could be due to the fact that cyst growth requires 
fluid secretion as well as cell proliferation. These signaling inhibitors have been shown to block 
ouabain-dependent cell proliferation (89), and the combined inhibition of proliferation and fluid 
secretion may account for the more complete inhibition observed in the microcyst cultures. 
Finally, in metanephric organ cultures, metanephroi were treated with Tyrphostin AG1478, PP2 
or U0126 in the presence of 8-Br-cAMP alone or combined with ouabain. The EGFR, Src and 
MEK inhibitors reduced the effect of ouabain to exacerbate cAMP stimulated growth of tubular 
cystic dilations in embryonic kidneys from Pkd1-/- mice, the phenotype in which ouabain’s effect 
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is most pronounced (Figure 4C).  Altogether, these results show that ouabain stimulates cAMP-
dependent fluid secretion and cyst growth through mediators of the Na,K-ATPase signaling 
pathway, involving EGFR, Src and MEK.  
 
Ouabain increases forskolin-induced short circuit current in ADPKD cell monolayers 
Fluid secretion by ADPKD cells is a key requirement for cyst growth and is regulated by 
apical anion secretion (84, 121). Measurement of short circuit current (Isc) in monolayers of 
ADPKD cells has been used extensively to study regulation of anion secretion across these 
monolayers (4, 12, 84, 103, 104), and this work has shown that forskolin and other cAMP 
agonists induce anion secretion in ADPKD monolayers mainly through the function of the 
apically located cystic fibrosis transmembrance conductance regulator (CFTR). The stimulatory 
effect of ouabain on cAMP and forskolin-induced fluid secretion may be due to an effect of the 
hormone on forskolin-stimulated Isc. To test this, monolayers of ADPKD cells were grown to 
confluence on permeable filter supports and treated either with control media or media 
containing 3 nM ouabain for 24 hours prior to measurement of short circuit current. As 
previously described (84, 104), forskolin induced an increase in short circuit current in 
monolayers of ADPKD cells (Figure 5). Interestingly, the monolayers treated with 3 nM ouabain 
exhibited an ~23% increase in the maximum response to forskolin treatment (Figure 5), 
indicating an increase in anion secretion across the monolayers. The increased Isc in both the 
ouabain treated and untreated monolayers was dependent on CFTR function as evidenced by 
the inhibition of the increased current by the specific CFTR inhibitor, CFTRinh172 (Figure 5). 
This effect of ouabain to increase anion secretion across ADPKD monolayers may contribute to 
the hormone’s effect to exacerbate cAMP- mediated fluid secretion and cyst growth in ADPKD.  
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Ouabain does not affect expression of CFTR or NKCC1 mRNA transcripts 
Fluid secretion and cyst growth in ADPKD depend on Cl- transport regulated by the apical 
CFTR and the basolateral N+,K+,2Cl--cotransporter (NKCC1) (84). To determine the effect of 
ouabain on expression of these two required ion transport proteins, levels of mRNA for CFTR 
and NKCC1 were measured by RT-PCR in ADPKD and NHK cells treated with ouabain or 8-Br-
cAMP alone or in combination. In both ADPKD and NHK cells, ouabain alone or in combination 
with cAMP had no effect on CFTR or NKCC1 mRNA expression (Figure 6). There was a slight 
increase in CFTR transcript expression in ADPKD cells treated with 8-Br-cAMP that was 
insignificant (p=0.314 vs. control). Additionally, the presence of ouabain with 8-Br-cAMP did not 
further increase the expression of CFTR transcripts in ADPKD cells (p=0.428 vs. control). This 
indicates that ouabain-induced increases in fluid secretion and cyst growth in ADPKD do not 
depend on a direct increase in expression of either CFTR or NKCC1. Future work will further 
define the specific molecular mechanism responsible for ouabain’s effect on fluid secretion and 
cyst growth in ADPKD. 
 
DISCUSSION 
 
Previous studies have demonstrated that ouabain stimulates proliferation of ADPKD cells 
through activation of the Na,K-ATPase signalosome (89, 90). Here, we show that ouabain also 
affects fluid secretion by the ADPKD epithelium. Ouabain enhances the vectorial movement of 
fluid from the basolateral to the apical side of ADPKD monolayers treated with either 8-Br-cAMP 
or forskolin. In addition, ouabain stimulates the forskolin-dependent growth of microcysts in 
ADPKD three-dimensional collagen cultures, which is an indicator of increased fluid delivery by 
the cells surrounding the lumen of the microcysts (44). Ouabain also promotes cAMP-
dependent tubular dilations in metanephric organ cultures of Pkd1m1Bei mice. These findings 
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highlight the importance of ouabain not only as a cell proliferation agent in ADPKD, but also as 
a factor that increases cyst volume content and growth. Additionally, ouabain increased the Isc 
response of ADPKD monolayers to forskolin treatment indicating that ouabain can augment the 
cAMP-dependent anion secretion regulated by CFTR that is a key requirement for fluid 
secretion and cyst growth in ADPKD. Therefore, ouabain influences two renal epithelial 
processes that are fundamental mechanisms for ADPKD cyst development. 
 
Exogenous and endogenous ouabain have been shown to elicit a variety of effects on 
kidney cells and tissues. These include changes in cell proliferation (65), cell detachment and 
death (2, 26), regulation of sodium reabsorption (18, 21, 88) and protection of the kidney from 
the adverse effects of malnutrition and serum deprivation (69). In the current study we show that 
ouabain modulates the amplitude of cAMP-dependent fluid secretion and cyst growth of ADPKD 
microcysts and metanephric organ cultures, providing evidence for a novel effect of ouabain on 
renal cells. These effects take place in response to nanomolar concentrations of ouabain, which 
are similar to those normally found in blood (100). This supports the pathophysiological 
relevance of ouabain as a modulating factor that contributes to progression of ADPKD cyst 
growth and the hypothesis that endogenous ouabain may contribute to cyst enlargement in 
ADPKD patients.  
 
While ouabain helps enhance fluid secretion and microcyst growth in ADPKD cells, it has no 
significant effect on normal human kidney cells, both in the absence or presence of 8-Br-cAMP 
or forskolin. Comparison of the fluid transport rates in the untreated NHK and ADPKD 
monolayers (Figure 1) show that both cell types absorb fluid in the absence of secretory 
agonsits. This is consistent with the normal function of  most renal epithelia to reabsorb the 
renal plasma filtrate. However, upon addition of 8-Br-cAMP or forskolin, ADPKD cells and NHK 
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cells can be induced to secrete fluid. This secretory response is greatly enhanced in ADPKD 
cells compared to NHK cells, and ouabain is augments this cAMP-dependent fluid secretion 
specifically in ADPKD cells.  Similarly, ouabain differentially affects metanephric kidneys, 
causing only a small increase in fractional cyst area in wild type metanephroi, and a more 
pronounced, and progressively larger increase in heterozygous and homozygous Pkd1 mutated 
metanephric kidneys. Therefore, cystic dilations induced by ouabain appear to correlate with the 
severity of the Pkd1m1Bei mouse phenotype. In agreement with these data, we have previously 
shown that ouabain differentially impacts the growth of NHK and ADPKD cells (90). We 
speculate that the difference in the effect  of ouabain may depend on the higher affinity that the 
Na,K-ATPase of ADPKD cells has for ouabain compared to NHK cells (90). This characteristic 
property of ADPKD cells may make the cystic cells more susceptible to circulating levels of 
ouabain, biasing them to respond to ouabain in an exacerbated manner compared to normal 
cells.   
 
Our previous and current observations suggest that the dual roles ouabain plays on the 
ADPKD epithelium, i.e. cell proliferation and fluid secretion, are affected in different ways. Thus, 
while ouabain enhances cell growth by itself (89, 90), it functions as an agonist together with 
other cyst inducing factors, such as cAMP and forskolin, to stimulate fluid secretion by the 
ADPKD epithelium. These effects produced by ouabain, acting either alone, or as a cofactor, 
suggest that different thresholds for the actions of ouabain may exist in the pathways or effector 
mechanisms leading to cell proliferation and fluid secretion in ADPKD cells. Although further 
experiments are needed to prove these possibilities, our results show that ouabain has 
complementary effects on cell proliferation and fluid secretion to promote ADPKD cyst 
development.   
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Regarding its mechanisms of action, we have found that ouabain’s contribution to ADPKD 
fluid secretion and cystogenesis involves essential components of the Na,K-ATPase signaling 
machinery. In this manner, Tyrphostin AG1478, PP2 or U0126 prevent the synergistic effect of 
ouabain on 8-Br-cAMP- and forskolin-induced cystogenesis, suggesting that activation of 
EGFR, Src, and the MAPK pathway are necessary for ouabain’s action. As previously reported, 
phosphorylation and stimulation of activity of these intracellular mediators is also required for 
the ouabain-dependent proliferation of ADPKD cells (89). Therefore, both the proliferative and 
secretory effects of ouabain are mediated through some common components of the Na,K-
ATPase signalosome. Interestingly, forskolin and cAMP mediate their effects by direct activation 
of the MAPK pathway (104, 121). Therefore, it is possible that, acting through EGFR and Src, 
ouabain can provide another route for activation of the MAPK pathway, with ouabain, cAMP and 
forskolin merging their effects at the level of the MAPK pathway.  
 
Ouabain and cAMP may also have common effects on the final effectors that regulate fluid 
secretion and cyst growth in ADPKD. Fluid secretion induced by cAMP in the ADPKD epithelium 
is mediated by activation of Cl- transport involving the apical CFTR and the basolateral  NKCC1 
(84). The enhancement of 8-Br-cAMP-dependent fluid secretion and of cyst growth induced by 
ouabain may be due to its combined effects with cAMP on CFTR and NKCC1. Our Isc results 
show that ouabain-treated monolayers exhibit an increased responsiveness to forskolin 
stimulation resulting in an increased cAMP-dependent Cl- current mediated by activation of 
CFTR. Factors favoring increased Cl- secretion in ADPKD monolayers are crucial regulators of 
increased fluid secretion and cyst growth (84, 123). While our results show ouabain does not 
directly increase the expression of either CFTR or NKCC1 mRNA, the glycoside may be 
influencing the effect of cAMP on these transporters by modulating phosphorylation or 
localization of CFTR or NKCC1 in ADPKD cells in a way that favors increased Cl- secretion. The 
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full mechanism governing ouabain-dependent increases in Cl- secretion requires further 
investigation, but the observation that ouabain-treated monolayers exhibit an augmented Isc 
response to forskolin indicates that physiologic concentrations of ouabain could exacerbate a 
key mechanism regulating fluid secretion in ADPKD. Furthermore, as noted previously (82), fluid 
secretion contributing to ADPKD cyst growth is a slow, chronic process. Therefore even modest 
changes in this secretory mechanism, when accumulated over many years, could account for 
substantial changes in cyst growth. The possibility that ouabain via the Na,K-ATPase could 
influence other ion transport systems distantly located on the cell plasma membrane is 
supported by previous work, which has shown that Na,K-ATPase-mediated ouabain signaling 
regulates the Na+/H+ exchanger (NHE3) at the apical membrane of pig kidney epithelial cell 
monolayers (21, 137). Additional studies in our laboratory will be directed to understanding the 
molecular basis through which ouabain augments transepithelial apical Cl-secretion and fluid 
transport in ADPKD. 
  
In conclusion, our results provide novel information for the role of ouabain on ADPKD 
cystogenesis. The stimulating action of ouabain on fluid secretion, in addition to the effect of this 
hormone to induce cystic cell proliferation, supports the important role of ouabain as an agent 
which can affect the pathophysiology and progression of ADPKD.  
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FIGURES  
 
 
FIGURE 1  Ouabain increases forskolin- and cAMP-dependent fluid secretion in ADPKD 
cells. Confluent cell monolayers were treated with 3 nM ouabain, 5 µM forskolin or 100 µM 8-
Br-cAMP alone, or ouabain combined with each of these agents.  Control monolayers were 
incubated in media with no treatments added. After 24 h, the fluid volume on the apical side of 
A) NHK and B) ADPKD cells monolayers was measured. Data are expressed as a fluid 
secretion rate, ul/h/cm2. Values are the mean + SEM of three (NHK) or four (ADPKD) 
experiments performed in cells obtained from different kidneys. (*) P < 0.01.   
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FIGURE 2  Ouabain increases forskolin-mediated microcyst growth in ADPKD cells. 
A,B) NHK and C,D) ADPKD cells were cultured within a three dimensional collagen gel and 
treated in the absence and presence of 3 nM ouabain, 5 μM forskolin, or both. Microcysts were 
maintained for 5-7 days after treatment and average total surface area of the formed microcysts 
per well  was measured. Data are expressed as microcyst average total surface area in cm2. 
Bars represent the means + SEM of six experiments performed in sextuplicate in cells obtained 
from six different ADPKD kidneys. (*) P < 0.05 vs control, (#) P < 0.05.  
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FIGURE 3  Ouabain increases cAMP-dependent cyst growth in metanephric organ 
cultures from Pkd1m1Bei mice. Metanephric cultures were treated with 30 nM ouabain or 100 
μM 8-Br-cAMP added separate or together. Images from the samples were captured and cyst 
area was measured. A,B) wild type Pkd1+/+ mice, (C,D) Pkd1+/- mice and (E,F) Pkd1-/- mice. Top 
panels (A,C and E) show representative images of metanephroi taken at days 0 to 4 after 
treatment. Bottom panels (B,D,F) depict the average fractional cyst area captured at day 4 for 
the different experimental conditions on the indicated Pkd1 phenotypes. Bars represent the 
means + SEM of three to eight kidneys depending on the treatment. (*) P < 0.05 vs. 8-Br-cAMP. 
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FIGURE 4  The cystogenic effect of ouabain is 
mediated via the EGFR-Src-MEK pathway.  
A) Monolayers of ADPKD cells were treated with the 
indicated inhibitors in the presence of forskolin (5 µM) or 
foskolin with ouabain (3 nM). Following 24h treatment, 
apical fluid was collected and measured. Bars represent 
the means + SEM of four to seven determinations on 
samples from cells obtained from two to four different 
ADPKD kidneys. Values different from samples treated 
with forskolin plus ouabain are indicated with an asterisk, 
with P < 0.05. B) ADPKD microcysts treated with the 
indicated inhibitors in the presence of forskolin (5 µM), 
with or without ouabain. After 5-7 days of growth, the 
average total surface area of all of the microcyst per well 
was determined.  Bars represent the means + SEM of six 
determinations in cells obtained from two or three ADPKD 
kidneys. Values different from samples treated with 
forskolin + ouabain are indicated with an asterisk, with P < 
0.05. C) Pkd1m1Bei mice organ cultures were treated with 
the indicated inhibitors in the presence of 8-Br-cAMP (100 
µM), with or without ouabain. At day 4 after treatment, 
images from the cultures were captured and cyst surface 
area was measured for each condition. Bars depict mean 
+ SEM for average fractional cyst area for the different 
experimental conditions, using two to three different 
kidneys. (*) P < 0.05 vs. 8-Br-cAMP plus ouabain.  
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FIGURE 5 Ouabain increases forskolin-induced short circuit current (Isc) in ADPKD 
monolayers. Monolayers of ADPKD cells, treated in the absence and presence of 3 nM for 24h, 
were mounted in Ussing chambers and Isc was measured by a dual voltage clamp device. 
Forskolin (5 µM) was added to media on the basolateral side of the monolayers to stimulate Isc, 
and CFTR(inh)-172 (10 µM), a specific CFTR inhibitor, was added apically to determine the 
contribution of CFTR. (A) Change in Isc (ΔIsc) from baseline for monolayers incubated in either 
control media or ouabain (3 nM) for 24 hours prior to measurement of Isc. Baseline currents 
were calculated as an average of the Isc reading for 1 to 2 minutes prior to the addition of 
forskolin. (B) Isc response of ADPKD monolayers to forskolin in the absence and presence of 
ouabain. Data are expressed as a percentage of the maximum forskolin response in untreated 
monolayers. Bars represent mean ± SEM for 9 control monlayers and 8 ouabain treated 
monolayers from different ADPKD kidneys. P < 0.05 compared to control. 
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FIGURE 6  Ouabain does not affect the expression of CFTR or NKCC1 mRNA in ADPKD 
or NHK cells. ADPKD cells and NHK cells were treated with 8-Br-cAMP (100 µM) or ouabain (3 
nM) alone or in combination. RNA was extracted from these cells, and real time quantitative 
PCR (RT-qPCR) and immunoblot were used to measure expression of CFTR (A, B) and 
NKCC1 (C,D) mRNA and protein levels, respectively. Transcript expression was normalized 
against expression of 18s RNA for each sample. Protein levels were normalized to 
corresponding untreated controls. Bars represent the mean ± SEM for 3 experiments each run 
with triplicate samples.  
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CHAPTER 4 
 
OUABAIN ALTERS ION TRANSPORT MECHANISMS TO  
ENHANCE FLUID SECRETION AND CYST GROWTH IN ADPKD 
 
INTRODUCTION 
 
The hormone ouabain has been shown to influence mechanisms that are essential for 
the ADPKD cystogenesis. Ouabain not only increases ADPKD cell proliferation, it also 
potentiates cAMP-dependent fluid secretion across ADPKD monolayers as well as cAMP-
dependent cyst growth of in vitro models of ADPKD (61). These effects requires the activation of 
the kinase Src, EGFR and the MAPK pathway (61, 89).  
Fluid secretion is a key component of ADPKD cystogenesis (37, 44). In ADPKD, fluid 
secretion depends on transepithelial secretion of Cl- across the apical membrane of cystic 
epithelia (104, 123). This Cl- transport provides a electrochemical stimulus to drive Na+ and, 
thus fluid, into the cystic lumen (105). The main apical regulator of this transepithelial Cl- 
tranport is the cystic fibrosis transmembrane conductance regulator (CFTR) (28, 104). Several 
studies have shown this transporter to be a crucial factor contributing to ADPKD fluid secretion 
and cystogenesis (20, 28, 81, 138). 
Experiments described here were carried out to determine the effectors mediating 
ouabain-induced ADPKD fluid secretion and cyst growth. We show that ouabain-dependent fluid 
secretion and cyst growth require the presence and activity of CFTR. Moreover, ouabain 
specifically augments forskolin-induced activation of CFTR. This is associated with ouabain-
dependent increases in membrane expression of CFTR as well as an increase in expression of 
an accessory protein, PDZK1, a potentiator of CFTR activity. Finally, ouabain treatment resulted 
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in decreased Na,K-ATPase membrane expression and ion transport which may have impacts 
on the fluid reabsorption potential of ADPKD epithelia.  
 
RESULTS 
 
Ouabain-induced cyst growth requires the presence and activity of CFTR 
Cyst growth in ADPKD requires fluid secretion driven by transepithelial Cl- transport 
(104, 123). This transport mechanism is regulated by the cAMP-dependent Cl- transporter, 
CFTR, at the apical membrane of cystic epithelial cells (28). Our previous work has shown that 
ouabain can potentiate cAMP- and forskolin-induced cyst growth as well as forskolin-stimulated 
fluid secretion (61). Additionally, ouabain can augment cAMP-dependent growth of cystic 
dilations in Pkd1m1Bei metanephric organ cultures from wild type (Pkd1+/+), heterozygous 
(Pkd1+/-), and homozygous null (Pkd1-/-) embryos. To determine the involvement of CFTR in  
ouabain-stimulated cyst growth, Pkd1m1Bei+/-  mice were crossed with Cftr+/- mice to obtain 
embryos deficient in PC-1 and CFTR. Magenheimer et. al. showed these mice fail to develop 
cystic dilations in response to 8-Br-cAMP treatment (81). Metanephric organ cultures were 
established at day E15.5 from Pkdm1Bei+/- mice with wild type (Pk1+/-; CF+/+) or null (Pkd1+/-; 
CF-/-) CFTR expression. Embryonic kidneys were treated with 100 μM 8-Br-cAMP in the 
presence and absence of 30 nM ouabain. Cultures were observed for 4 days, and cystic area 
was measured after 4 days of treatment. In agreement with previous studies (81), embryonic 
kidneys lacking CFTR showed no cyst growth in response to 8-Br-cAMP (Figure 1). 
Furthermore, in contrast to kidneys with wild type levels of CFTR, there was no ouabain-
dependent induction of cystic dilations in the metanephric cultures lacking CFTR expression 
(Figure 1). These data suggest that ouabain increases growth of cystic dilations in the Pkd1m1Bei 
embryonic kidneys via a mechanism requiring the presence of CFTR.   
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Several studies have shown that ADPKD cells grown in a three dimensional collagen 
matrix will form individual cysts lined by a polarized epithelium, and this method is commonly 
used to investigate mechanisms influencing growth of ADPKD renal cysts (89, 104). Previously 
we showed that endogenous concentrations of ouabain can augment forskolin-induced cyst 
growth in this in vitro setting (61). To further investigate the requirement for CFTR in ouabain-
induced cyst growth, microcyst cultures of ADPKD cells were established, as previously 
described (61, 89). Microcyst cultures were treated with and without ouabain (3 nM) in the 
presence and absence of forskolin (5 μM). Additionally, some cultures were treated with a 
specific CFTR inhibitor, CFTR(inh)-172 (10 µM), and forskolin (5 μM) in the absence and 
presence of ouabain (3 nM). CFTR(inh)-172 has been shown previously to block growth of 
microcysts derived from a canine cell line model of ADPKD (138). Figure 2 shows that ouabain 
itself has no effect on microcyst formation and growth. In contrast, ouabain  augmented 
forskolin-induced microcyst. The presence of CFTR(inh)-172 abolished mycrocyst formation. 
These data, along with results from the metanephric organ cultures, indicate that the 
potentiating effect that ouabain has on cAMP- and forskolin-induced cyst growth requires the 
presence and activity of CFTR. 
 
Ouabain-enhanced fluid secretion requires CFTR activity 
Our previous work has shown that physiologic concentrations of ouabain can augment 
forskolin-induced fluid secretion across ADPKD monolayers (61). To determine the involvement 
of CFTR in this pro-secretory effect of ouabain, fluid secretion by ADPKD monolayers was 
analyzed in the presence of the specific CFTR inhibitor, CFTRinh-172.  ADPKD cells were 
grown on permeable membrane supports until a tight monolayer was formed, as previously 
described (61). Following overnight starvation in 0.002% FBS, monolayers were treated for 24 
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hours with and without ouabain (3 nM) in the absence and presence of forskolin (5 μM). 
Additionally, CFTR(inh)-172 was added to the apical media of some monolayers treated with 
forskolin (5 μM) alone or in the presence of ouabain (3 nM). Following treatment, media on the 
apical side of each monolayer was collected and measured. In agreement with our previous 
results (61), ouabain augmented forskolin-induced fluid secretion across monolayers of ADPKD 
cells (Figure 2). Fluid secretion in the presence of CFTR(inh)-172 was not significantly 
increased above baseline values. Importantly, ouabain had no augmenting effect on fluid 
secretion observed in the presence of CFTR(inh)-172 (Figure 2). These results indicate that, in 
the setting of CFTR inhibition, ouabain does not enhance a secretory response in ADPKD 
monolayers. Moreover, ouabain-dependent potentiation of forskolin-induced fluid secretion 
requires the presence of an active CFTR.  
 
Ouabain enhances forskolin-dependent Cl- transport in ADPKD cells 
 Fluid secretion across ADPKD monolayers is regulated by the transepithelial transport of 
Cl- (104). Previously, we showed that chronic treatment of ADPKD monolayers with physiologic 
concentrations of ouabain enhanced forskolin-induced increases in short circuit current of the 
cells indicating a ouabain-dependent increase in anion secretion (61). This increase was 
blocked by the application of CFTR(inh)-172. To further examine the effect ouabain has on the 
activity of CFTR in ADPKD cells, Cl- efflux assays were performed. Cells were plated in 96-well 
plates and grown for 24 h in media containing 1.0% FBS. Following overnight serum starvation, 
cells were treated with and without ouabain (3 nM) for 48 hours. Cells were then loaded with the 
fluorescent indicator dye, MQAE (7 mM), in a Cl- containing buffer, maintaining the presence of 
ouabain. Following treatment and dye loading, cells were washed with dye-free, Cl--containing 
buffer, and forskolin was added for 10 min during the final wash to cells with and without 
ouabain. For all treatment conditions, parallel samples were analyzed in the absence and 
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presence of CFTR(inh)-172. To induce Cl- efflux, cells were switched from a Cl--containing 
buffer to a Cl- free buffer maintaining the presence of experimental treatment. The change in 
flourescence was monitored in a plate reader taking measurements every minute for 10 
minutes. Cl- efflux was determined as the change in fluorescence of a sample at a given time 
point (Ft) from the initial flouresecnce (F0) prior to inducing Cl
- efflux. The portion of fluorescence 
change (Ft-F0) sensitive to CFTR inhibition was calculated to determine the CFTR-dependent Cl
- 
efflux.  Representative traces of the CFTR-dependent fluorescence change are shown in Figure 
4A. Average Ft-F0 values were determined to analyze the effect of the various treatments on the 
activation state of CFTR (Figure 4B). CFTR-dependent Cl- efflux was not affected by ouabain 
treatment alone. Forskolin caused a significant increase in CFTR-dependent Cl- efflux, 
consistent with the role of forskolin as a cAMP-agonist in ADPKD cells. Interestingly, in cells 
treated with ouabain for 48 h, forskolin had an enhanced effect on CFTR-dependent Cl- efflux. 
This is in agreement with our previous findings in short-circuit current analysis. These results 
indicate that ouabain treatment alone has no effect on CFTR-dependent Cl- efflux. However, 
treatment with nanomolar concentrations of ouabain alters ADPKD cells in way that allows 
enhanced forskolin-stimulated Cl- secretion via the CFTR. 
 
Ouabain alters expression of CFTR and PDZK1in ADPKD cells 
Previous work has shown a correlation between the expression level of CFTR and the 
extent of cyst growth in ADPKD (28). Our past work has shown that ouabain has no effect on 
the total cellular expression of CFTR in ADPKD cells (61). However, studies from Zhang et. al. 
showed that low doses of ouabain were sufficient to increase membrane delivery of mutant 
CFTR in a bronchial epithelial cell line (144). To determine if ouabain may be affecting the 
expression of CFTR at the plasma membrane in ADPKD cells, biotinylation studies were 
conducted. Monolayers of ADPKD cells were established on permeable membrane supports. 
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Following serum starvation, monolayers were treated without and with 3 nM ouabain in the 
absence and presence of 5 μM forskolin for 24h-48h. Monolayers were then labeled with biotin 
and lysed in RIPA buffer. The biotinylated lysates were immunoprecipated overnight with 
streptavidin-conjugated magnetic beads. The immunoprecipitated products were separated by 
SDS-PAGE (7.5% gel) and electrotransferred to nitrocellulose membranes. An antibody to the 
C-terminus of human CFTR was used to analyze the plasma membrane expression of CFTR. 
Figure 5 shows that ouabain alone was sufficient to increase membrane expression of CFTR in 
ADPKD monolayers at 48h. These results indicate that chronic ouabain exposure leads to 
increased expression of CFTR at the membrane of ADPKD cells. Enhancing the level of CFTR 
membrane expression may create an altered cellular phenotype allowing for augmented 
responses to secretory agonists that target CFTR activation. 
  
Expression and activity of CFTR can be regulated by protein-protein interactions (47). 
Many proteins involved in regulation of CFTR act by binding to a PDZ-domain in the C-terminus 
of CFTR (46, 47, 102). PDZ-domains are amino acid sequences that mediate protein-protein 
interactions (47). Previous studies uncovered a particular PDZ-domain containing protein, 
PDZK1, that may play an important role in regulation of CFTR activity (126). In particular, 
coexpression of CFTR with PDZK1, caused potentiation of PKA-dependent activity of CFTR. To 
determine whether PDZK1 may be associated with ouabain-induced changes in Cl- transport in 
ADPKD cells, expression levels of PDZK1 were analyzed by western blot in ADPKD cells 
treated with and without 3 nM ouabain for 24h. Ouabain treatment of ADPKD cells caused a 
significant increase in the expression levels of PDZK1 (Figure 6). This increase in PDZK1 
expression is consistent with a ouabain-induced potentiation of cAMP-dependent Cl- transport in 
ADPKD cells. Taken together these results indicate that nanomolar concentrations of ouabain 
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can elicit changes in protein expression consistent with ouabain-induced augmentation of 
cAMP-dependent anion and fluid secretion. 
 
Ouabain decreases membrane expression of Na,K-ATPase 
The Na,K-ATPase is responsible for regulating sodium and water reabsorption in normal 
renal epithelia. While fluid secretion in ADPKD epithelia has been extensively studied, there is 
little information regarding fluid reabsorption mechanisms in this epithelium. It is possible that 
alterations leading to increased accumulation of fluid in the cystic lumen may result from a 
combination of increased fluid secretion and decreased fluid reabsorption. To determine the 
effect of ouabain on factors that may be regulating fluid reabsorption in ADPKD epithelia, 
ouabain-dependent Na,K-ATPase expression was determined by biontinylation and 
immunocytochemistry analysis of monolayers of ADPKD cells. Ouabain treatment of ADPKD 
monolayers resulted in a significant decrease in membrane expression of Na,K-ATPase (Figure 
7). This decreased membrane expression could be visualized by immunocytochemistry (Figure 
7A) and also quantified by immunoblot analysis of biotinylated monolayers using an antibody 
specific for α1-Na,K-ATPase (Figure 7B). This is consistent with results from other studies in 
LLC-PK1 cells (73, 74, 137). These results indicate that physiologic concentrations of ouabain 
can influence the membrane expression of the Na,K-ATPase. Specifically, ouabain treatment 
leads to decreased levels of Na,K-ATPase at the plasma membrane of ADPKD cells. 
 
Ouabain decreases Na,K-ATPase-mediated ion transport 
 Decreased membrane expression of the Na,K-ATPase could have significant effects on 
the ion transport directly and indirectly regulated by the Na,K-ATPase. To determine the effect 
of physiologic concentrations of ouabain on Na,K-ATPase-dependent ion transport rubidium 
uptake assays were performed. ADPKD cells were grown to confluence on permeable 
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membrane supports. Following serum starvation, cells were treated with and without 3 nM 
ouabain for 30 min. Rubidium uptake was then analyzed in the monolayers. Figure 8A shows 
there was approximately 20% less rubidium uptake in ouabain-treated monolayers compared to 
control monolayers. This is consistent with a ouabain-dependent reduction in membrane 
expression of the Na,K-ATPase causing reduced Na,K-ATPase-mediated ion transport.  
  
Na,K-ATPase-mediated ion transport is responsible for maintaining a low intracellular 
concentration of sodium required for normal cellular function. Additionally, by regulating 
intracellular sodium concentrations in renal epithelial cells, the Na,K-ATPase can regulate 
sodium-dependent fluid reabsortion. Assays were performed to analyze the effect of low 
concentrations of ouabain on the intracellular concentration of sodium in ADPKD cells. Cells 
were incubated in media containing the fluorescent dye, sodium green tetra acetate, with and 
without 3 nM ouabain for 30, 60, and 90 minutes. At each time point analyzed, ouabain caused 
a significant increase in the intracellular sodium concentration. This result is in agreement with 
our other results showing a ouabain-induced decrease in Na,K-ATPase membrane expression 
and ion transport (137). Altogether, these data suggest that oubain may be altering the ion 
transport systems regulating fluid reabsorption in cystic epithelia in a manner that favors less 
fluid reabsorption. 
 
DISCUSSION 
 
Investigation of the mechanisms by which humoral factors affect progression of ADPKD 
yields important pathophysiologic information that can be used for the potential development of 
therapeutic approaches to treat ADPKD. Previously, we demonstrated that ouabain is an agent 
that augments cystogenic mechanisms in ADPKD. Specifically, physiologic concentrations of 
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ouabain can induce proliferation of ADPKD cells and enhance cAMP-dependent fluid secretion 
and cyst growth of in vitro models of ADPKD. Results from the current study provide important 
information on the mechanisms by which ouabain stimulates fluid secretion and cyst growth in 
ADPKD. Ouabain enhanced forskolin-induced cyst growth and fluid secretion via CFTR-
dependent mechanisms in metanephric organ cultures from Pkd1m1Bei mice as well as ADPKD 
microcyst cultures and in monolayers of ADPKD cells. Ouabain-dependent potentiation of 
forskolin-stimulated cyst growth and fluid secretion required the presence and activity of CFTR. 
Cells treated with ouabain exhibited an increased CFTR-dependent Cl- efflux in response to 
forskolin. This ouabain-induced potentiation of Cl- efflux may be due to changes at the level of 
protein expression. Ouabain treatment of ADPKD monolayers led to an increased membrane 
expression of CFTR. A ouabain-induced increase in CFTR membrane expression is consistent 
with the enhanced forskolin-induced Cl- efflux observed in ADPKD cells treated with ouabain.  
A role for ouabain in affecting membrane expression of CFTR has been reported by 
Zhang, et al using a human bronchial epithelial cell line expressing a mutated form of CFTR 
(144). In this study, treatment with nanomolar concentrations of ouabain resulted in increased 
total expression and membrane expression of  CFTR which was correlated with increased 
CFTR function. Mechanistically, this study showed that ouabain-dependent increases in CFTR 
membrane expression were associated with altered mechanisms of protein trafficking in the 
cells. In particular, ouabain treatment led to a decrease in chaperone proteins (HSP8/Hsc70 and 
HSPA1L/Hsp70) that are involved in protein folding and regulation of ER-associated protein 
degradation.  Additionally, ouabain decreased expression of components of the COPII complex 
which is involved in the export of proteins from the Golgi. Altogether, these results demonstrate 
that ouabain exerts important effects on the intracellular trafficking mechanisms responsible for 
the targeting of CFTR to the cell plasma membrane. Further studies are required to confirm the 
involvement of the effect of ouabain in the cell biology of CFTR trafficking in ADPKD cells .  
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ADPKD cells, derived from the epithelium lining renal cysts express normal, non-
mutated CFTR. CFTR is known to be expressed in the mammalian kidney, and several studies 
have shown it to be a crucial factor in ADPKD cystogenesis (20, 28, 81, 138). Cyst growth and 
formation in ADPKD depend on the continuous secretion of fluid into the growing cyst lumen 
(37). This fluid secretion is mainly regulated by transepithelial Cl- secretion which depends on 
the activity of CFTR (28, 123). By mediating the cAMP-dependent apical secretion of Cl-, CFTR 
generates the stimulus driving Na+ and fluid into the growing cyst lumen (40, 104).  
Regulation of CFTR expression is complex and depends on the interaction of a variety of 
chaperones and scaffolding proteins (47). These interactions are associated with regulation of 
CFTR protein trafficking, membrane localization, and intermolecular interaction with other ion 
transporters. In particular, several PDZ-domain containing proteins have been demonstrated to 
be involved CFTR regulation (102, 126). Our results show ouabain treatment of ADPKD cells 
led to an increase in the expression of a particular PDZ-domain containing protein, PDZK1. This 
protein has been implicated in increasing dimerization of membrane expressed CFTR leading to 
increases in PKA-dependent activation(126). Importantly, in these co-expression studies, 
PDZK1 alone caused no increase in CFTR activity. Rather, expression of PDZK1 with CFTR 
facilitated increased CFTR activation in response to PKA signals. Such a mechanism is 
consistent with our observations in ADPKD cells that ouabain, which alone causes no change in 
fluid secretion or anion transport, allows for increased forskolin- and cAMP-induced fluid 
secretion, anion secretion, and in vitro cyst growth. Additionally, the results of our Cl- efflux 
assay demonstrate that ouabain treatment alone does not activate CFTR-dependent Cl-
transport. Rather, cells treated with ouabain have an increased response to forskolin-induced 
activation of CFTR-mediated Cl- efflux. This ouabain-dependent increase in responsiveness to 
cAMP-dependent signals in ADPKD cells may be elicited by alterations at the protein 
expression level. By increasing expression of PDZK1 and membrane expression of CFTR, 
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ouabain may be inducing a  phenotype in ADPKD cells with augmented responses to cAMP-
dependent signals resulting in increased cAMP-induced fluid secretion and cyst growth.  
Other important physiologic agents affecting ADPKD progression have been shown to 
affect cAMP-dependent pathways in ADPKD cells (117, 121). For example, arginine 
vasopressin (AVP), can activate cAMP-dependent pathways in ADPKD cells leading to 
increased Cl- transport and, ultimately, increased cyst growth (11, 89). These effects of AVP in 
ADPKD cells can be abolished by treatment with an antagonist of the AVP receptor (89). This 
highlights the pathophysiologic importance of agents affecting cAMP-dependent mechanisms in 
ADPKD. A direct effect of ouabain on the expression of CFTR at the plasma membrane 
identifies a downstream effector where ouabain-induced effects may be converging with cAMP-
dependent mechanisms known to be important for ADPKD progression. Previous work in our 
laboratory demonstrated a role for ouabain in activating cell proliferation in ADPKD cells (89, 
90). This proliferative effect of ouabain was mediated by activation of Src, EGFR, and the MAPK 
signaling pathway. Similarly, we have shown that ouabain-induced changes in fluid secretion 
and cyst growth depend on these same intracellular signaling events. However, the proliferative 
effect of ouabain is induced by ouabain alone, while the effects of ouabain on fluid secretion and 
cyst growth are only observed in conjunction with treatments increasing intracellular cAMP. It is 
likely that ouabain-induced signals which lead to inceased fluid secretion and cyst growth in 
ADPKD compliment the cAMP-dependent signals already activated in the cells. Our results here 
identify CFTR as a potential downstream effector where ouabain and cAMP-dependent 
signaling may converge leading to a potentiation of ADPKD fluid secretion and cyst growth. 
Fluid secretion in ADPKD has been shown to be mediated by active anion secretion 
across the apical membrane creating a stimulus for Na+ and water to follow resulting in 
increased intraluminal fluid accumulation (104). Normal renal tubules reabsorb most of the fluid 
in the glomerular filtrate, largely by sodium-dependent mechanisms regulated by the Na,K-
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ATPase. However, reabsorption mechanisms have not been widely studied in cystic epithelial 
cells. Our results suggest that ouabain may be decreasing fluid reabsorption across cystic 
epithelia by decreasing Na,K-ATPase membrane expression and Na,K-ATPase mediated ion 
transport. While physiologic concentrations of ouabain do not completely abolish Na,K-ATPase 
activity, we have observed a slight decrease in Na,K-ATPase activity in response to nanomolar 
concentrations of ouabain. Decreases in this ion transport mechanism are associated with an 
increase in intracellular Na+ concentrations in ADPKD cells exposed to ouabain. By altering 
mechanisms governing Na+ transport in ADPKD cells, oubain may be reducing the ability of 
these cells to reabsorb fluid. Such an effect would likely exacerbate the secretory phenotype of 
cystic epithelia leading to increased fluid accumulation in the growing cysts. 
Studies conducted in normal porcine epithelial cells have demonstrated a similar effect 
of nanomolar concentrations of ouabain on Na,K-ATPase membrane expression and ion 
transport (73, 74, 137). These studies have shown that ouabain can regulate transcellular 
sodium transport mechansims by a direct effect on the apical expression of the 
sodium/hydrogen exchanger (NHE3) and the Na,K-ATPase in proximal tubule cells (21, 92). 
More investigation is needed to define the specific role of ouabain in regulating sodium transport 
and fluid reabsorption in ADPKD epithelia. However, results from our study and from other 
laboratories support the hypothesis that ouabain is a physologic factor that may decrease fluid 
reabsorption mechanisms in ADPKD epithelia to further favor fluid secretion over reabsorption 
and lead to enhanced accumulation of fluid in growing renal cysts. 
In conclusion, our current results identify specific ouabain-dependent mechanisms that 
may be responsible for ouabain’s effect on fluid secretion and cyst growth in ADPKD. We 
suggest that ouabain acts on ADPKD cells to confer a phenotype more responsive to cAMP-
dependent secretory agonists while also reducing mechanisms of fluid reabsorption to further 
enhance fluid secretion across ADPKD epithelia. Our current results support the important role 
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ouabain may have as a physiologic agent affecting the progression of renal cyst growth in 
ADPKD. 
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FIGURES
 
FIGURE 1 Ouabain-enhanced cyst growth in metanephric kidneys requires CFTR. 
Embryonic kidneys (E15.5) from Pkd1m1Bei+/-; Cftr+/+ and Pkd1 m1Bei +/-;Cftr-/- mice were 
isolated and placed into culture in media containing 100 μM 8-Br-cAMP in the absence and 
presence of 30 nM ouabain. (A) Representative images of metanephic kidneys in culture. (B) 
Average fractional cyst area was calculated after four days of treatment. Bars represent the 
means ± SEM for 5 to 8 kidneys depending on the treatment. (*) P < 0.05 vs. 8-Br-cAMP 
treatment alone in the Cftr+/+ kidneys; (#) P < 0.05 vs. corresponding treatments in Cftr+/+ 
kidneys. 
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FIGURE 2 Ouabain-enhanced ADPKD microcyst growth requires CFTR. Microcyst cultures 
were established by seeding ADPKD cells within a three-dimensional collagen matrix. Cultures 
were treated without and with 5 μM forskolin in the absence and presence of 3 nM ouabain. 
Additionally, some cultures were treated with 10 µM CFTR(inh)-172 and forskolin (5 μM) in the 
absence and presence of ouabain. Untreated, control cultures remained in defined media alone 
during the treatment period. After 5-7 days total cyst surface area of the microcyst cultures was 
measured. (A) Representative images of microcyst cultures for each of the indicated treatments. 
(B) Average total surface area of microcyst cultures was measured for each treatment condition. 
Bars represent means ± SEM for microcyst cultures grown in sextuplicate with cells from 
different ADPKD kidneys. (*) P < 0.05 vs. forskolin alone; (#) P < 0.01 vs. forskolin+ouabain 
treatment. 
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FIGURE 3 Ouabain-enhanced fluid secretion in ADPKD monolayers requires CFTR. 
Confluent monolayers of ADPKD cells were treated without and with 5 μM forskolin in absence 
and presence of 3 nM ouabain. Monolayers were also treated with 10 μM CFTR(inh)-172 and 5 
μM forskolin in the absence and presence 3 nM ouabain. Untreated, control monolayers were 
incubated in media containing no experimental agents. After 24h, the volume of fluid on the 
apical side of each monolayer was removed and measured. Data are expressed as fluid 
secretion rate, ul/h/cm2. Bars represent the fluid secretion rate mean ± SEM for monolayers 
grown in triplicate from different ADPKD kidneys. (*) P < 0.05; (#) P < 0.01 vs. forskolin+ouabain 
treatment. 
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FIGURE 4 Ouabain augments forskolin-induced, CFTR-dependent Cl- efflux in ADPKD 
cells. ADPKD cells grown in 96-well plates were treated without and with 3 nM ouabain for 48 
hours. Cells were loaded with MQAE, and then Cl- efflux was induced by swithching to a Cl--free 
buffer. Prior to Cl- efflux induction, forskolin (5 μM) was added to cells with and without 
Flourescent measurements were taken every minute for 10 minutes. Cl- efflux was determined 
from the difference between the fluorescence of a sample at a give time (Ft) and the initial 
fluorescence of that sample prior to inducing Cl- efflux (F0). The portion of the flourescence 
change (Ft-F0) sensitive to CFTR(inh)-172 was determined to be CFTR-dependent Cl- efflux. 
(A) Representative trace of CFTR-dependent Cl- efflux for samples exposed to the indicated 
treatments. (B) Ft-F0 at the plateau of each efflux curve was calculated for each treatment 
condition and expressed relative to control flouresence change. Bars represent means ± SEM 
for 6 different experiments using ADPKD cells from different kidneys. (*) P < 0.05 vs. untreated 
control; (#) P < 0.01. 
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FIGURE 5 Ouabain increases CFTR membrane expression in ADPKD monolayers. 
Confluent monolayers of ADPKD cells were  treated without and with ouabain (3 nM) for 24h-
48h. Following treatment, membrane proteins from the monolayers were isolated by 
biotinylation and streptavidin immunoprecipitation. These samples were analyzed by SDS-
PAGE and immunoblot using an antibody specific for human CFTR. Bars represent CFTR 
membrane expression for each treatment relative to untreated control levels and normalized to 
tubulin expressed as means ± SEM for 4 determinations using cells from different ADPKD 
kidneys . A representative immunoblot is shown below the graph. (*) P < 0.05 vs. untreated 
control. 
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FIGURE 6 Ouabain increases PDZK1 expression in ADPKD cells. Cells were treated without 
and with ouabain (3 nM) for 24h. Following treatment, cells were lysed and equal amounts of 
cell lysate were separated by SDS-PAGE and then immunoblotted using an antibody specific for 
human PDZK1. Protein expression was determined by densitometry. Bars represent PDZK1 
expression relative to untreated control levels and normalized to tubulin. Data are expressed as 
means ± SEM for 3 determinations using cells from different ADPKD kidneys. A representative 
immunoblot is displayed below the graph. (*) P < 0.05 vs. untreated control. 
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FIGURE 7 Ouabain reduces membrane expression of Na,K-ATPase in ADPKD cells. Na,K-
ATPase membrane expression was analyzed by immunocytochemistry and biotinylation. (A) 
Immunofluorescence microscopy of confluent cultures grown on filter supports treated with 
ouabain for 24 h and labeled for the α1 subunit of the Na,K-ATPase.  Top panels show z-line 
views positioned at the lines indicated in the x-y views shown in the bottom panels.  Ap, apical; 
Bl, basolateral side of the cells. (B) Western blot analysis following biotinylation of surface 
proteins.  Na,K-ATPase membrane expression was determined using antibodies specific for the 
α1 and β1 subunits of the Na,K-ATPase.  Bars represent the mean ± SEM of 3 determinations 
performed on cells obtained from different ADPKD kidneys.  (*) P < 0.01 vs untreated control.   
     
 
A
B
Ap
Bl
- + Ouabain
Ouabain
β1 Na,K-ATPase
α1 Na,K-ATPase
N
a
,K
-A
T
P
a
s
e
m
e
m
b
ra
n
e
 e
x
p
re
s
s
io
n
 
(r
e
la
ti
v
e
 le
v
e
ls
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
100 kDa -
50 kDa -
37 kDa -
- +
*
61 
 
 
 
 
FIGURE 8 Ouabain reduces Na,K-ATPase-mediated ion transport in ADPKD cells. (A) 86Rb 
uptake in ADPKD cells. Confluent monolayers of ADPKD cells were treated with and without 
ouabain (3 nM) for 24h. 86Rb uptake was measured and data are expressed as 86Rb uptake 
relative to uptake in untreated control monolayers. Bars represent means ± SEM of 6 
determinations performed on cells obtained from different ADPKD kidneys.  (*) P < 0.05 vs 
untreated control. (B) Intracellular sodium, [Na]i, was determined using sodium green tetra 
acetate. ADPKD cells were incubated in media containing the flourescent dye with and without 
ouabain (3 nM) for the indicated times. Mean flourescence intensity of each sample was then 
analyzed and expressed relative to the untreated control for each time point. Bars represent 
mean ± SEM for experiments performed on cells obtained from different ADPKD kidneys.  (*) P 
< 0.05 vs untreated control for each corresponding time point.   
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CHAPTER 5 
 
ABNORMAL EXPRESSION OF THE POLYCYSTIN-1 C-TAIL ALTERS  
THE RESPONSE OF M-1 COLLECTING DUCT CELLS TO OUABAIN 
 
INTRODUCTION 
 
A great amount of work has been devoted to understanding the pathophysiology of 
ADPKD; however, the relationship between defects in the polycystins (PC-1 and PC-2) and the 
cystic phenotype remains unclear. Different in vitro models and mouse models have been 
generated in which deletion, mutation, and overexpression of the Pkd1 gene have been 
performed. These have provided evidence connecting PC-1 function to known signaling 
pathways (116). Studies reported here utilized a mouse cortical collecting duct cell model, in 
which inducible overexpression of the C-terminal cytosolic domain of PC-1 confers the cells with 
an ADPKD proliferative phenotype in response to cAMP. This behavior, typical of ADPKD cells, 
is not observed in normal kidney cells, or in collecting duct cells lacking PC-1 C-tail 
overexpression, which respond to cAMP by decreasing cell growth (107). The effect of PC-1 C-
tail overexpression can be explained by a dominant-negative loss-of-function mechanism that 
causes disruption of the normal polycystin signaling pathway in the cells (107).   
 
The following series of experiments examined whether the ADPKD phenotype of these 
M-1 cortical collecting duct cells, which overexpress the PC-1 C-tail, affects the response of the 
cells to ouabain. Results of this investigation indicate that acquisition of the cystic phenotype by 
PC-1 C-tail overexpression increases the affinity of M-1 cortical collecting duct cells to ouabain, 
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induces ouabain-stimulated intracellular signaling events in these cells and stimulates their 
ability to proliferate and secrete anions, all features typical of ADPKD cells.  
 
RESULTS 
 
Overexpression of polycystin-1 C-tail enhances ouabain proliferative effects of M1 cells 
Previous work in our laboratory had shown that human ADPKD epithelial cell cultures 
derived from the cystic epithelium of ADPKD kidneys, respond to nanomolar concentrations of 
ouabain by increasing cell proliferation. In contrast, human normal kidney cell growth is not 
significantly affected by ouabain.  (89, 90). It has been shown that overexpression of the C-tail 
portion of PC-1 in M-1 cortical collecting duct cells provides these cells with changes in their 
proliferative response to agonists that increase intracellular cAMP levels, reminiscent of the 
behavior observed in ADPKD cystic cells (107). We investigated if M-1 cells expressing the C-
tail of PC-1 also responded to ouabain with exacerbated cell growth. For this, we treated M-1 
C20 and M-1 C17 cells with dexamethasone and then incubated them in the absence or 
presence of various concentrations of ouabain for 24 hours. While both M-1 C20 and M-1 C17 
cells have been transfected with a dexamethasone-inducible PC-1 C-tail construct, only the M-1 
C20 clone expresses the PC-1 construct after induction. The lack of PC-1 C-tail expression in 
the M-1 C17 clone makes these cells an adequate control for studying the effects of the PC-1 
construct. This property of the M-1 clones has been previously described (107). Following 
ouabain treatment, cell proliferation was measured after 24 h. As shown in Figure 1, ouabain 
stimulated proliferation of M-1 C20 cells in a dose-dependent manner. The maximal proliferative 
effect of ouabain was observed at ouabain concentrations between 3 x 10-9 M and 10-7 M. At 
doses above 10-7 M, cell growth was progressively inhibited, agreeing with the notion that 
relatively high amounts of ouabain are toxic for the cells. In contrast to M-1 C20 cells, ouabain 
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did not significantly affect proliferation of M-1 C17 cells. These results demonstrate that 
overexpression of the C-terminal portion of PC-1 confers a ouabain-dependent proliferative 
phenotype to M-1 cells. 
  
M-1 C20 cells respond to ouabain by activating the ERK1/2 pathway    
ADPKD cells have been shown to respond to nanomolar concentrations of ouabain by 
activating the Na,K-ATPase signaling apparatus (89). One of the main downstream intracellular 
intermediates of this signaling system is the kinase ERK1/2. To determine whether ouabain 
utilizes signaling pathways in M-1 C20 cells common to those of ADPKD cells, we studied the 
ouabain-dependent phosphorylation of ERK1/2 in M-1 C20 and M-1 C17 cells. After induction of 
PC-1 C-tail expression with dexamethasone, cells were treated with different amounts of 
ouabain for 30 min and the total and phosphorylated forms of ERK1/2 were analyzed by 
immunoblot using lysates from the cells. As shown in Figure 2A, the levels of phosphorylated 
ERK1/2 were not significantly changed by ouabain in M-1 C17 cells.  In contrast, ouabain 
caused a dose-dependent increase in ERK1/2 phosphorylation in M-1 C20 cells, with a maximal 
level of phosphorylation induced at 3 x 10-8 M ouabain (Figure 2B). These results show that 
ouabain exerts effects on the cells expressing the PC-1 C-tail by activating the ERK1/2 
pathway.  
 
Ouabain activates the EGFR-Src-MEK-ERK pathway in M-1 C20 cells 
Important intermediates upstream of ERK1/2 in the ouabain-induced, Na,K-ATPase-
mediated pathway of ADPKD cells include Src, EGFR and MEK. To investigate whether this 
signaling pathway is activated by ouabain in the M-1 C20 cells induced to express PC-1 C-tail, 
we studied the phosphorylation of ERK1/2 as a downstream indicator of ouabain signaling, in 
the absence and presence of EGFR, Src and MEK inhibitors. M-1 C20 cells were treated with 
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and without 3 x 10-8 M ouabain, in the absence and presence of tyrphostin AG1478, PP2, and 
U0126 and 30 min later, ERK phosphorylation was determined. The inhibitors were used at 
concentrations that have been shown to be optimal for blocking EGFR, Src, and MEK activation 
of ADPKD cells (89). Figure 3A shows that ouabain-dependent phosphorylation of ERK1/2 in M-
1 C20 cells is prevented by inhibition of EGFR, Src, and MEK. 
 
To further determine if activation of the EGFR-Src-MEK-ERK signaling pathway is 
responsible for ouabain-stimulated proliferation of M-1 C20 cells, proliferation assays were 
performed on these cells after treatment with and without 3 x 10-8 M ouabain in the absence and 
presence of tyrphostin AG1478, PP2, or U0126 for 24 hours. Figure 3B shows that inhibition of 
EGFR, Src, and MEK prevented the proliferation that ouabain induced in M-1 C20 cells. These 
data indicate that in M-1 C20 cells, ouabain-dependent activation of the EGFR-Src-MEK-ERK 
signaling pathway is necessary to cause cell proliferation. 
 
Ouabain enhances forskolin-dependent anion secretion in M-1 C20 monolayers 
Previous results indicated that overexpression of the C-terminal domain of PC-1 alters 
the ion transport properties of M-1 C20 cells, enhancing the ATP-stimulated apical Cl- 
conductance of the cells (59, 129). Measurement of short circuit current, Isc, has been used 
extensively as an indicator of anion fluid secretion in cystic cell monolayers (44, 61, 84, 123). 
We previously used this method and showed that ouabain augments a forskolin-induced 
increase of short circuit current in ADPKD monolayers (61). Here, we determined if expression 
of the PC-1 C-tail endows the cells with modified ion transport properties in response to 
ouabain. For this, we studied the effect of ouabain on forskolin-induced anion secretion of M-1 
C20 and M-1 C17 cells. Cells were grown on permeable filter supports until a tight monolayer 
was formed. Following dexamethasone treatment and overnight starvation in 0.002% FBS, the 
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monolayers were treated with and without 3 x 10-8 M ouabain for 24 hours and short circuit 
currents were measured. Ouabain had no significant effect on the forskolin-induced Isc of M-1 
C17 cells (Figure 4A and 4C). In contrast, ouabain treatment of M-1 C20 monolayers resulted in 
an approximately 40% augmentation of the forskolin-induced increase in Isc (Figure 4B and 
4D). The forskolin-induced increase in Isc of M-1 C20 cells was inhibited by addition of 
CFTR(inh)-172, a specific inhibitor of CFTR.  To assess whether the effect of ouabain on 
forskolin-induced anion secretion was mediated via the Na,K-ATPase signaling cascade, we 
tested the sensitivity of the ouabain-dependent increase of short circuit currents to the Src 
kinase inhibitor, PP2. PP2 prevented the ouabain-dependent increases in forskolin-stimulated 
anion secretion of M-1 C20 cells.  In contrast PP2 did not significantly affect the basal Isc in the 
absence of ouabain, indicating that this inhibitor specifically interfered with ouabain-Na,K-
ATPase signaling (Figure 4B and 4D). Altogether, these data demonstrate that ouabain 
enhances forskolin-induced, CFTR-dependent Isc in cells overexpressing the C-tail of PC-1. 
This effect is mediated by activation of the intracellular tyrosine kinase, Src.  
 
Overexpression of the PC-1 C-tail increases the ouabain affinity of M1 cells 
In ADPKD cells, a fraction of Na,K-ATPase has an abnormally high sensitivity to 
ouabain. This is indicated by a biphasic response to ouabain inhibition, with approximately 20% 
of the Na,K-ATPase of ADPKD cells presenting a ouabain inhibition constant in the nanomolar 
range. The remaining Na,K-ATPase activity of ADPKD cells retains a relatively lower sensitivity 
to ouabain inhibition, which is characteristic of normal kidney cells (90). We determined whether 
overexpression of the PC-1 C-tail in cortical collecting duct cells, which confers an ADPKD 
phenotype, affected the sensitivity of these cells to ouabain.  For this, the ouabain inhibition 
profile of Na,K-ATPase activity was tested on homogenates of M-1 C20 cells after induction of 
overexpression of PC-1 C-tail with dexamethasone. As a control, M-1 C17 cells which do not 
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express the PC-1 construct were used. As shown in Figure 5A, Na,K-ATPase from M-1 C20 
cells exhibited a bimodal dose-response curve to ouabain, presenting components with high 
and low sensitivity to ouabain. In contrast, M-1 C17 cells only presented the Na,K-ATPase 
fraction with low sensitivity to ouabain, which is typical for normal rodent kidney cells (15). The 
calculated Ki values for ouabain inhibition of Na,K-ATPase activity and relative amounts of each 
Na,K-ATPase population are depicted in Table 1. As shown, approximately three-fourths of the 
Na,K-ATPase of M-1 C20 cells had an inhibition constant (Ki) for ouabain in the millimolar 
range, similar to that of M-1 C17 cells. The remaining one-fourth of the Na,K-ATPase of M-1 
C20 cells had a Ki for ouabain in the nanomolar range. These results indicate that a portion of 
the Na,K-ATPase of M-1 C20 cells exhibits an abnormally increased sensitivity to ouabain, 
which is not found in the M-1 C17 cells not expressing PC-1 C-tail. 
 
One of the mechanisms that dictates the response of Na,K-ATPase to ouabain is the 
presence of different isoforms of its catalytic α subunit. Four different Na,K-ATPase α 
polypeptides (α1, α2, α3 and α4), are expressed in mammalian cells. These isoforms are 
characterized by distinct kinetic properties, among which is their particular response to ouabain 
(15). Normally, renal epithelial cells largely express the α1 isoform of the Na,K-ATPase, which is 
relatively insensitive to ouabain. The presence of this population of Na,K-ATPase with high 
sensitivity to ouabain suggests that M-1 C20 cells may be mis-expressing one of the Na,K-
ATPase isoforms that has a high affinity for ouabain. To investigate this, expression of the 
different Na,K-ATPase α isoforms was determined at the mRNA and protein levels. As shown in 
Figures 5B and 5C, both M-1 C20 and M-1 C17 cells only expressed the α1 isoform of Na,K-
ATPase. This demonstrates that the increased ouabain-sensitivity observed in M-1 C20 cells is 
not due to an altered expression of α isoforms of the Na,K-ATPase. 
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Discussion 
 
Results from our studies show that overexpression of a PC-1 C-tail construct in M-1 cells 
induces a phenotypic change with respect to the affinity and response of the cells to ouabain. 
This was reflected by increased ouabain-dependent cell proliferation and enhancement of 
forskolin-induced transepithelial anion secretion, as well as an augmented sensitivity of Na,K-
ATPase activity to ouabain. Overexpression of the C-terminal domain of PC-1 has been shown 
to confer M-1 cells with phenotypic characteristics of ADPKD cells, likely through a dominant-
negative mechanism (107). In particular, M-1 cells expressing an excess of the PC-1 cytosolic 
segment, exhibit aberrant cell proliferation and enhanced transepithelial Cl- secretion (59, 107). 
Both of these characteristics are typical of the ADPKD phenotype. Our data here suggest that 
an increased ouabain sensitivity is another distinctive property of these cells. This ouabain 
sensitive phenotype mimics our previous findings in human ADPKD cells and allows ouabain to 
stimulate both cell proliferation and apical anion secretion, which are two essential components 
of ADPKD cystogenesis (61, 89, 90). Moreover, these effects take place at ouabain 
concentrations that are similar to those normally circulating in plasma. Therefore, our current 
findings further support the importance of ouabain as a cystogenic factor in ADPKD. 
Additionally, the ouabain-responsive phenotype makes the cells more prone to respond to 
ouabain and may be relevant to the progression of renal ADPKD cysts. 
  
In M-1 cells expressing a PC-1 C-tail construct, ouabain induced cell proliferation 
through activation of the Na,K-ATPase signaling pathway. Similar to ADPKD cells, the effects of 
ouabain on M-1 C20 cell proliferation are abolished by tyrphostin AG1478, PP2 and U0126, 
suggesting that the mechanism of action of ouabain in M-1 C20 cells requires activation of 
EGFR, Src, MEK and ERK1/2. Therefore, ouabain-induced signaling in M-1 C20 cells is 
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mediated through components that are common to those of the Na,K-ATPase signalosome of 
other cells. In addition, these intracellular messengers constitute important mediators of the 
cystic ADPKD phenotype in response to cAMP (121). Moreover, aberrant overexpression of the 
C-terminal cytosolic tail of PC-1 has been implicated in dysregulation of several signaling 
pathways, including the response of the MAPK pathway to cAMP stimulation (107). In this 
manner, it is possible that ouabain, acting independently through EGFR-Src-MEK-ERK, 
converges on the same, already hyperactive, cAMP-stimulated pathway of cystic cells. 
  
While previous work has shown that overexpression of the PC-1 C-tail enhances ATP-
stimulated Cl- secretion (59), our work is the first to investigate the effect of the C-tail construct 
on forskolin-induced anion secretion. In our studies, forskolin-stimulated increases in Isc were 
comparable between M-1 C17 and M-1 C20 cells, however, ouabain treatment enhanced the 
forskolin-induced anion secretion only in M-1 C20 cells. Additionally, the ouabain enhanced, 
forskolin-stimulated Isc resulting from PC-1 C-tail overexpression in M-1 C20 cells, was 
sensitive to the specific CFTR inhibitor, CFTR(inh)-172. This indicates that the acquired cystic 
phenotype of the cells follows molecular mechanisms for anion secretion that are similar to 
those described in native ADPKD epithelium. However, in contrast to our studies in human 
ADPKD cells (61), inhibition of CFTR did not completely abolish the ouabain-dependent and 
forskolin-induced Cl- current in these monolayers. The small remaining Isc fraction, resistant to 
CFTR(inh)-172, suggests that M-1 C20 cells have an additional pathway for the apical 
movement of Cl- that is independent from CFTR. On the other hand, the similar degree of Isc 
inhibition achieved by CFTR(inh)-172 in M-1 C20 monolayers treated with and without ouabain, 
suggests that the component of the forskolin-induced increase in Isc that was augmented by 
ouabain treatment is due to specific activation of the CFTR Cl- channel. The dependency of Isc 
current on the activity of CFTR agrees with that previously reported in ADPKD cells and 
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supports the role of ouabain in the regulation of ion transport systems of the cell plasma 
membrane (137). The ouabain enhanced, forskolin-stimulated Cl- current in the M-1 C20 cells 
overexpressing the PC-1 C-tail was blocked by PP2. This suggests that both proliferation and 
Cl- secretion induced by ouabain in M-1 C20 cells involves Src, a key component of the Na,K-
ATPase signaling machinery. 
  
At present the link between abnormalities in expression of PC-1 and the final effectors 
involved in ADPKD cystogenesis are not clear. The exacerbated ouabain-responsive phenotype 
resulting from overexpression of PC-1 C-tail in M1 cells is also poorly understood. However, we 
found that M-1 C20 cells have a population of Na,K-ATPase that has an increased sensitivity to 
ouabain. Our observation that M-1 C20 cells, similar to M-1 C17 cells, only express the α1 
isoform of the Na,K-ATPase indicates that the molecular basis for the change in ouabain 
sensitivity is not based on mis-expression of one of the ouabain sensitive α isoforms of the 
Na,K-ATPase. Similar results were obtained in ADPKD cells, which express the Na,K-ATPase 
α1 subunit that is normally found in kidney epithelial cells. Alternatively, the increase in ouabain 
affinity may depend on the interaction of Na,K-ATPase with other proteins. Through the use of 
the yeast two-hybrid system, the cytosolic tail of PC-1 has been shown to interact with the Na,K-
ATPase (143). We previously found that exogenous co-expression of the transmembrane and 
C-tail domains of PC-1 and the Na,K-ATPase, in Sf-9 insect cells, augments the sensitivity of 
the Na,K-ATPase to ouabain (90). Currently, additional experiments are being conducted to 
confirm this possibility.  
 
 In conclusion, we show that, overexpression of a membrane anchored C-tail domain of 
PC-1 induces a ouabain-responsive phenotype in mouse cortical collecting duct cells. The 
similarity of the ouabain effects in M-1 C20 cells with those of primary ADPKD cells is important, 
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since M-1 C20 cells represent a valuable system to study the role and mechanisms of action of 
ouabain in a cell model for ADPKD in which PC-1 function, specifically, has been rendered 
abnormal.  
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FIGURES         
 
 
                
FIGURE 1 Ouabain increases proliferation of M-1 C20 cells. Cells were plated in 96-well 
culture dishes. After 24 hours in culture, cells were treated with 1 µM dexamethasone for 48 
hours. Following an overnight starvation in medium with 0.002% FBS, the indicated 
concentrations of ouabain were added for 24 hours. Proliferation was measured using the 
CellTiter 96 assay. Points represent the changes in cell proliferation relative to untreated 
controls. Symbols are the mean ± SEM (n=5). Asterisks indicate values statistically different 
from the respective controls not treated with ouabain, with P < 0.05. 
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FIGURE 2 Ouabain increases ERK1/2 phosphorylation in M-1 C20 cells. A) M1-C17 and B) 
M-1 C20 cells (1 × 105) were plated in 6-well culture dishes. After 24 hours, expression of PC-1 
C-tail was induced with 1 µM dexamethasone for 48 hours. Following overnight starvation in 
media supplemented with 0.002% FBS, cells were treated with the indicated concentrations of 
ouabain for 30 minutes. Samples were lysed and ERK1/2 phosphorylation (p-ERK) was 
analyzed by immunoblot. Bands in the blots were quantified by densitometric analysis. Bars in 
the graphs represent the ratio of p-ERK to total ERK levels for each ouabain concentration, 
normalized to the untreated controls. Representative immunoblots are shown under each graph. 
Data represent the mean ± SEM (n = 7). The asterisk indicates statistically significant values, 
with P < 0.05 vs. untreated control.  
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FIGURE 3 Ouabain increases ERK1/2 phosphorylation and proliferation of M-1 C20 cells 
via the EGFR-Src-MEK pathway. A) Dependency of ERK phosphorylation on the EGFR-Src-
MEK pathway. Expression of PC-1 in M-1 C20 cells was induced with 1 µM dexamethasone for 
48 h and then, after overnight starvation in medium with 0.002% FBS, cells were treated with 3 
X 10-8 M ouabain  in the absence and presence of the indicated inhibitors for 30 minutes. 
Samples were lysed and ERK1/2 phosphorylation was analyzed by immunoblot. Bars represent 
the ratio of p-ERK to total ERK for each treatment condition normalized to the untreated control. 
A representative blot is shown under the graph. Data are the mean ± SEM (n = 4). Symbols 
indicate statistically significant values, with (*) P < 0.05  vs. untreated control and (#) P < 0.05 
vs. ouabain treatment. B) Dependency of M-1 C20 cell proliferation on the EGFR-Src-MEK 
pathway. Cells were treated as described in A, except that cell proliferation was measured 24 h 
later, using the CellTiter 96 assay kit.  Bars represent cell proliferation relative to the untreated 
control. Bars are the mean ± SEM (n=3). Symbols indicate statistically significant values, with (*) 
representing  P< 0.001, compared to untreated controls and (#) and (##) indicating P<0.01 and 
P<0.001 respectively, compared to ouabain treated samples. AG1478, PP2 and UO126 refer to 
the EGFR, Src kinase and MEK inhibitors, respectively. 
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FIGURE 4 Ouabain augments forskolin-induced increases in short circuit current of M-1 
C20 cell monolayers.Confluent cell cultures were grown on permeable filter supports and PC-1 
C-tail expression was induced with 1 µM  dexamethasone for 48 h. After overnight starvation, 
cells were treated with and without 3 x 10-8 M ouabain for 24 hours. To determine if ouabain-
induced potentiation of anion secretion in M-1 C20 cells involves Src, the effect of PP2 was 
tested. Short-circuit currents were then analyzed in Ussing chambers. Benzamil (10 µM) was 
applied to the apical side of the monolayer to block sodium transport across the epithelium. A -
B) Representative traces of M-1 C17 and M-1 C20 monolayers, treated in the absence or 
presence of ouabain and with or without the presence of PP2 for M-1 C20 cells. C and D) 
Quantification of the forskolin-induced increase in short circuit current in M-1 C17 and M-1 C20 
monolayers respectively. Bars represent maximal forskolin responses as a percent of the 
untreated controls. Bars are the mean ± SEM (n=3-9 monolayers for each condition). The 
asterisk indicates statistically significant values compared to untreated controls. In M-1 C20 
cells, (#) indicates differences vs. forskolin + ouabain, P < 0.05. 
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FIGURE 5 Na,K-ATPase from M-1 C20 cells exhibits increased sensitivity to ouabain, 
despite a normal expression pattern of Na,K-ATPase α isoforms.  A) Dose-response curves 
for the inhibition of Na,K-ATPase by ouabain. Cells were treated with 1 µM dexamethasone for 
48 hours and were harvested and homogeneized. Na,K-ATPase activity was measured in the 
absence and presence of the indicated concentrations of ouabain. Data are expressed as 
percent of the Na,K-ATPase activity in the absence of ouabain. Curves represent the best fit of 
the data, which favored one (M-1 C17) versus two (M-1 C20) Na,K-ATPase populations with 
different affinities for ouabain. Values are the mean ± SEM of five experiments. B-C) Expression 
profile of Na,K-ATPase α isoforms in M-1 C20 and M-1 C17 cells. Cells were harvested after 48 
hr induction with 1 µM dexamethasone. (B) PCR amplification was performed using primers to 
specific regions of each isoform. Amplified cDNA fragments were run in agarose gels. The sizes 
of the amplified fragments were as follows: α1 isoform, 173 bp; α2 isoform, 143 bp; α3 isoform, 
104 bp; α4 isoform, 120 bp. (C) Analysis of Na,K-ATPase α polypeptides was performed by 
immunoblot, using antibodies specific to each α isoform. As positive controls, cDNA and protein 
lysates from mouse kidney (for α1), brain (for α2 and α3) and testis (for α4) were used.  
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Table 1 Kinetic parameters for the interaction of Na,K-ATPase from M-1 C20 and M-1 C17 
cells with ouabain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Kinetic parameters for  the interaction of Na,K-ATPase from M-1 C20 and M-1 C17 cells with ouabain. 
1.4 + 3.2 x 10-9
Cell type
Inhibition constant, Ki (M)
M-1 C20
6.3 + 3.7 x 10-5
1.4 + 0.3 x 10-4
Relative amounts (%)
High affinity Low affinity
M-1 C17
High affinity Low affinity
24.6 + 4.3 75.4 + 2.1
100.0 + 0.0
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CHAPTER 6 
 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
ADPKD is a systemic disorder characterized most dramatically by the progressive 
growth of renal cysts (37). Several non-genomic factors influence ADPKD cyst formation and 
growth (117, 121). The results of the current study have discovered, through the study of 
ADPKD, a novel role for ouabain. Specifically, physiologic concentrations of ouabain influence 
ADPKD cystogenesis by concomitantly inducing cell proliferation and potentiating cAMP-
dependent mechanisms of ADPKD fluid secretion. These effects of ouabain are exerted through 
the Na,K-ATPase and involve activation of Na,K-ATPase-signaling apparatus, including the Src-
EGFR-MEK pathway. Moreover, ouabain-dependent enhancement of fluid secretion and cyst 
growth takes place at concentrations similar to those seen in human plasma. This supports the 
role of ouabain as a physiologic agent that influences renal cyst growth and progression of 
ADPKD. 
 
Previous work has shown that ouabain alone is sufficient to enhance proliferation of 
ADPKD cells (89, 90). However, results of the current study showed no effect of ouabain 
treatment alone in ADPKD fluid secretion or cyst growth. However, ouabain was sufficient to 
augment forskolin- and cAMP-dependent increases in fluid secretion and growth of ADPKD 
microcysts as well as growth of cyst-like dilations in metanephric kidneys from the Pkd1m1Bei 
mouse model. These effects required the presence and activity of CFTR. Additionally, the 
potentiating effect of ouabain on fluid secretion and cyst growth required long-term  treatment, 
suggesting an effect of ouabain on protein expression mechanisms in ADPKD cells. Further 
investigation into a potential effect of ouabain on mechanisms regulating ADPKD fluid secretion 
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revealed that  ouabain increased membrane expression of CFTR in monolayers of ADPKD 
cells. Furthermore, ouabain treatment increased the expression of PDZK1, an accessory protein 
associated with potentiation of PKA-dependent activation of CFTR. Both of these mechanisms 
may lead to increased CFTR-mediated effects in ADPKD cells. Consistent with this possibility, 
cells treated with ouabain exhibited enhanced CFTR-dependent increases in short-circuit 
current and Cl- efflux. These results indicate an important mechanism mediating ouabain-
induced augmentation of fluid secretion and cyst growth in ADPKD.  
 
Fluid secretion in ADPKD is dependent on active Cl- secretion via the apically located 
CFTR (28, 104, 123). CFTR-dependent Cl- transport in ADPKD cells is regulated by cAMP. By 
directly affecting expression and function of CFTR, ouabain induces a phenotypic alteration in 
ADPKD cells characterized by enhanced sensitivity to cAMP agonists. This results in an 
augmented secretory potential of cystic epithelial cells exposed to physiologic concentrations of 
ouabain. Furthermore, oubain treatment of ADPKD cells resulted in decreased Na,K-ATPase 
membrane expression and ion transport. Given the important role for the Na,K-ATPase in 
regulating fluid reabsorption mechanisms in renal epithelia, a decreased expression of this 
transporter at the plasma membrane may cause a reduction in fluid reabsorption across ADPKD 
epithelia. Taken together, these effects on CFTR and the Na,K-ATPase demonstrate ouabain-
dependent mechansisms influencing crucial effectors regulating progression of renal cyst 
growth in ADPKD. 
 
Fluid secretion and cyst growth in ADPKD are significantly influenced by intracellular 
cAMP (121). The potentiating effect of ouabain on cAMP-dependent fluid secretion and cyst 
growth suggests that intracellular events activated by ouabain and cAMP converge at some 
downstream target in the cells. Effects of ouabain on fluid secretion and cyst growth in this study 
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were blocked by inhibitors of Src, EGFR, and MEK. These intracellular signaling molecules are 
known to be important mediators of ouabain-induced, Na,K-ATPase-mediated signaling 
involved in ADPKD cell proliferation. The mitogenic effect of cAMP in ADPKD is also mediated 
by activation of the MEK-ERK pathway. Thus, activation of ERK1/2 is a potential downstream 
site where ouabain-induced and cAMP-dependent signals may converge. Results from the 
current study also indicate that the CFTR in ADPKD cells may be another important 
downstream effector where ouabain-induced and cAMP-dependent signals converge resulting 
in increased fluid secretion and cyst growth. Future investigations will be required to more fully 
analyze the interaction of signals induced by ouabain and cAMP agonists in ADPKD cells. 
  
CFTR-dependent Cl- secretion represents the main cAMP-dependent mechanism that 
regulates fluid secretion and cyst growth mechanisms in ADPKD (121). Many circulating factors, 
such as vasopression (AVP), epidermal growth factor (EGF), and prostaglandins, can increase 
cAMP levels in ADPKD cells and cause activation of CFTR-dependent Cl- secretion (83, 104, 
117, 121). AVP is of particular importance to renal cyst growth since renal epithelia are 
continuously exposed to this hormone as the kidneys work to concentrate urine and maintain 
proper serum osmolality. This continuous supply of AVP likely creates a state of constant 
activation of CFTR in ADPKD epithelia resulting in ongoing fluid secretion in renal cystic 
epithelia. In a similar manner, the abnormally high ouabain affinity of cystic epithelial cells, may 
be causing circulating concentrations of ouabain to preferentially, and continuously, stimulate 
Na,K-ATPase-mediated signaling events. This may provide an ongoing potentiation of 
mechanisms of cyst growth and  progression of renal disease in ADPKD. 
  
Results of the current study raise the interesting possibility that a balance between fluid 
secretion and fluid reabsorption exists across ADPKD epithelia. Intraluminal fluid accumulation 
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is undoubtedly required for progressive renal cyst growth (44), and many studies have defined 
in detail the secretory mechanisms regulating this fluid accumulation (104, 105). However, 
mechanisms of fluid reabsorption across ADPKD epithelia have not been studied as 
extensively. Normal renal tubules reabsorb most of the fluid and electrolytes present in the 
glomerular filtrate, and for many years fluid secretion by renal tubules was not recognized as an 
important physiologic process in the kidney (45). However, pioneering studies by Grantham and 
colleagues clearly showed the potential for normal renal tubules to secrete fluid and electrolytes 
(38, 41, 42). This important discovery lead to a more complete understanding of renal tubular 
physiology in which a dynamic balance of reabsorptive and secretory processes modifies the 
glomerular filtrate along the length of the nephron. In the same way, important mechanistic 
information regarding fluid transport in ADPKD will likely be uncovered by further examining the 
role of fluid reabsorption mechanisms in cystic epithelia.  
  
This also leads to questions regarding the basic pathophysiologic switch that induces 
ADPKD epithelia to have such a dramatic secretory phenotype. ADPKD cysts arise from cells 
lining normal renal tubules (54). These tubules have the capability to reabsorb enormous 
quantities of fluid on an ongoing basis. However, in ADPKD, cells with disrupted polycystin 
function, switch to a secretory phenotype. Future studies could uncover important mechanistic 
information concerning ADPKD pathogenesis by investigating the nature of this switch from a 
reabsorptive to a secretory phenotype observed in ADPKD epithelia.   
 
The potentiating effect of ouabain on ADPKD fluid secretion and cyst growth was 
specific for ADPKD cells and microcysts. Nanomolar concentrations of ouabain failed to 
augment cAMP-dependent effects on fluid secretion or cyst growth analyzed using normal 
human renal epithelial cells. These results, in conjunction with previous results showing 
82 
 
ADPKD-specific effects of ouabain, emphasize the need to understand the nature of the 
increased ouabain affinity of ADPKD cells.  
  
Results from studies using M-1 cells indicate a specific, novel link between PC-1 and the 
ouabain affinity of M-1 mouse cortical collecting duct cells. M-1 cells overexpressing a 
dominant-negative construct of the PC-1 C-tail (M-1 C20 cells) exhibited an abnormally high 
affinity for ouabain despite normal expression of the α1β1 Na,K-ATPase isozyme. In M-1 C20 
cells, ouabain caused cell proliferation as well potentiation of forskolin-stimulated anion 
secretion.  Ouabain elicited these effects via activation of the Src-EGFR-MEK-ERK pathway, 
similar to mechanisms demonstrated in human ADPKD cells. These effects were not seen in a 
control cell line which did not express the abnormal PC-1 C-tail construct. This suggessts that 
loss of PC-1 function is sufficient to induce a ouabain sensitve phenotype in murine renal 
epithelial cells. These results demonstrate a novel, functional link between PC-1 and the 
ouabain affinity of the renal Na,K-ATPase. Furthermore, the results of these studies indicate 
that M-1 cells overexpressing the PC-1 C-tail offer an effective in vitro model to further 
investigate ouabain-dependent mechanisms in cystic epithelial cells. 
 
The molecular explanation for a functional link between PC-1 and Na,K-ATPase 
signaling is unclear. The increased ouabain affinity of the Na,K-ATPase in M-1 C20 may be due 
to altered intracellular calcium levels in these cells. The intracellular ionic composition can have 
significant impacts on functional properties of the Na,K-ATPase, and studies have shown that 
intracellular Ca2+ concentrations, in particular, can influence the ouabain affinity of the Na,K-
ATPase (141) . This is an intriguing possibility given the known pathogenic importance of 
abnormally low Ca2+ concentrations in ADPKD cells (134, 136). Increased ouabain affinity of 
cystic epithelial cells may be another consequence of disrupted Ca2+ levels in ADPKD cells. 
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Another related possibility is that alteration in signals derived from the C-tail of PC-1 are causing 
an altered ouabain affinity in M-1 C20 and ADPKD cells. The M-1 C20 cells overexpress a 
dominant-negative construct of the PC-1 C-tail. This portion of the PC-1 protein has been 
implicated in numerous different signaling pathways, some of which regulate intracellular Ca2+ 
concentrations (91). Investigation of a potential link between the effect of PC-1 C-tail derived 
signaling events and ouabain affinity of epithelial cells may uncover important basic information 
regarding PC-1 function and factors regulating Na,K-ATPase function. 
  
Growth of renal cysts in ADPKD is an exponential process occuring over many years 
(43). Any alteration that may increase the slope of the growth curve of renal cystogenesis, no 
matter how slight, is likely to have an extremely important effect on cystic disease that is 
compounded over the lifetime of a patient affected by ADPKD. Since ouabain can influence both 
proliferative and secretory responses in cystic epithelial cells, this hormone emerges as a 
physiologic factor that may potentially have a large influence on the growth of ADPKD cysts. 
The possible pathophysiologic role of endogenous ouabain in ADPKD is supported by data from 
pre-clinical and clinical studies. High-salt diets can increase circulating levels of endogenous 
ouabain (9). A high-salt diet fed to Han:SPRD rats, a model of polycystic kidney disease, led to 
increased renal disease in the rats (64). Additionally, analysis of data from The Consortium for 
Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) has found baseline urinary 
sodium exretion (a marker of sodium intake) to be an independent predictor of increased renal 
cyst growth in ADPKD (115, 118). This supports the possibility that ouabain may be a circulating 
factor contributing to increased progression of renal disease in ADPKD. 
 
The importance of therapeutically targeting physiologic factors that affect progression of 
ADPKD cyst growth is underscored by the results of the TEMPO3:4 trial. This study evaluated 
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the effectiveness of tolvaptan, an antagonist of the renal vasopressin receptor (V2R), in ADPKD 
patients. Tolvaptan treatment resulted in slower rates of cyst growth and renal functional decline 
for patients receiving the intervention (114). The results of this trial emphasize the importance 
and confirm the rationale for targeting physiologic agents influencing mechanisms of cyst growth 
in ADPKD. 
 
By this rationale, further investigation into ouabain-induced mechanisms in ADPKD is 
clearly warranted. Moreover, future work should address strategies to inhibit ouabain-dependent 
effects. The ability to therapeutically target ouabain has been demonstrated by studies using 
Rostafuroxin (17β-[3-furyl]-5β-androstan-3β,14 β,17α-triol; PST2238) as a therapy for essential 
hypertention (31). Rostafuroxin selectively displaces ouabain from its binding site on the Na,K-
ATPase, and, thus, acts as an inhibitor of endogenous ouabain. Rostafuroxin has been shown 
to lower blood pressure in rats and humans in some studies. It would be interesting to 
investigate the effectiveness of Rostafuroxin in antagonizing ouabain-dependent potentiation of 
ADPKD cyst growth.  
 
In conclusion, the results of this study demonstrate important, novel effects of ouabain 
on mechansisms of fluid secretion and cyst growth in ADPKD. Ouabain is an endogenous factor 
that can affect the two processes required for enhanced ADPKD cyst growth, cell proliferation 
and fluid secretion. Ouabain mediates an effect on mechanisms of fluid secretion by influencing 
expression and activity CFTR to induce a phenotypic change in ADPKD cells characterized by 
enhanced responsiveness to cAMP agonists. Additionally, these results raise that possibility that 
fluid reabsorption mechanisms may be contributing to the aberrant fluid secretion observed in 
ADPKD cystic epithelia. Ouabain may be modifying mechanisms of reabsorption in a manner 
that favors enhanced fluid secretion by further augmenting the disbalance between fluid 
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secretion and reabsorption in ADPKD epithelia. Altogether, the results of the current study 
provide a significant advancement in our understanding of ouabain’s mechanisms of action in 
ADPKD and support the role of ouabain as a physiologic agent that may be influencing the 
progression of renal disease in ADPKD. 
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